<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000561" GROUP_ID="DEPRESSN" ID="221999102308564228" MERGED_FROM="" MODIFIED="2008-11-01 13:47:50 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Short title (no longer in use): Antidepressants versus placebo for depressed elder&lt;/p&gt;&lt;p&gt;Old title: - TSC OK - AWAITING REVIEWER OK - Antidepressants versus placebo for the depressed elderly&lt;/p&gt;" NOTES_MODIFIED="2008-11-01 12:43:38 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="025" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2008-11-01 13:47:50 +0100" MODIFIED_BY="Rachel Churchill">
<TITLE>Antidepressants versus placebo for the depressed elderly</TITLE>
<CONTACT MODIFIED="2008-11-01 13:47:50 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="8318" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Kenneth</FIRST_NAME><LAST_NAME>Wilson</LAST_NAME><EMAIL_1>kw500505@liverpool.ac.uk</EMAIL_1><EMAIL_2>kw500505@liverpool.ac.uk</EMAIL_2><ADDRESS><ORGANISATION/><ADDRESS_1>Psychiatry</ADDRESS_1><ADDRESS_2>EMI Academic Unit, Univ of Liverpool, St Catherine's Hospital, Church Road</ADDRESS_2><CITY>Birkenhead</CITY><ZIP>L42 0LQ</ZIP><REGION>Wirral</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 604 7333</PHONE_1><FAX_1>+44 151 653 3441</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-01 13:47:50 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="8318" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Kenneth</FIRST_NAME><LAST_NAME>Wilson</LAST_NAME><EMAIL_1>kw500505@liverpool.ac.uk</EMAIL_1><EMAIL_2>kw500505@liverpool.ac.uk</EMAIL_2><ADDRESS><ORGANISATION/><ADDRESS_1>Psychiatry</ADDRESS_1><ADDRESS_2>EMI Academic Unit, Univ of Liverpool, St Catherine's Hospital, Church Road</ADDRESS_2><CITY>Birkenhead</CITY><ZIP>L42 0LQ</ZIP><REGION>Wirral</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 604 7333</PHONE_1><FAX_1>+44 151 653 3441</FAX_1></ADDRESS></PERSON><PERSON ID="7909" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Patricia</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Mottram</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>pgmottrm@liverpool.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Liverpool</ORGANISATION><ADDRESS_1>Academic Unit</ADDRESS_1><ADDRESS_2>St Catherine's Hospital</ADDRESS_2><CITY>Church Road</CITY><ZIP>CH42 0LQ</ZIP><REGION>Birkenhead</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 151 604 7333</PHONE_1><FAX_1>+44 151 653 3441</FAX_1></ADDRESS></PERSON><PERSON ID="5B2B637482E26AA201D1E7656E175DD9" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Anushta</FIRST_NAME><LAST_NAME>Sivananthan</LAST_NAME><POSITION>Consultant Psychiatrist</POSITION><ADDRESS><DEPARTMENT>Older People's Mental Health</DEPARTMENT><ORGANISATION>Cheshire and Wirral Partnership NHS Foundation Trust</ORGANISATION><CITY>Liverpool</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="19515" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>A</FIRST_NAME><LAST_NAME>Nightingale</LAST_NAME><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>EMI Academic Unit</ORGANISATION><ADDRESS_1>St Catherine's Hospital</ADDRESS_1><CITY>Liverpool</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-01 12:42:32 +0000" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Minor update: 25/02/05&lt;/p&gt;" NOTES_MODIFIED="2008-11-01 12:42:32 +0000" NOTES_MODIFIED_BY="Rachel Churchill">
<UP_TO_DATE>
<DATE DAY="15" MONTH="10" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="10" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="2" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2001"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="1" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="15" MONTH="10" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-01 12:43:38 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-01 12:43:12 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-01 12:43:12 +0000" MODIFIED_BY="[Empty name]">Antidepressants compared with placebos for depressed older people</TITLE>
<SUMMARY_BODY>
<P>Seventeen RCTs were identified by the systematic literature search that met our inclusion criteria and provide suitable data for analysis. We analysed these 17 placebo trials examining the efficacy of antidepressant treatment in older people. Just under 2000 patients were entered into the meta analysis. TCAs, SSRIs and MAOIs proved effective in both institutionalised and community patients. Low dose TCA treatment may be effective but further studies are needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Depression warranting intervention is found in ten percent of people over the age of 60. Older depressed people are more likely to die than non-depressed. Relatively few receive therapeutic interventions, and those that do, tend to receive low dose antidepressant therapy. Depression in older people is thought to differ in terms of aetiology, presentation, treatment and outcome than in younger people. Concomitant physical illness and increasing social, physical and neurophysiological diversity are associated with the ageing process. Consequently drug treatment of older patients is often carried out in institutions and on patients suffering from multiple physical problems.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy of antidepressant medication compared with placebo in the treatment of depression in older patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The search strategy incorporated: electronic literature searches of databases held by the Cochrane Collaboration Depression, Anxiety and Neurosis Review Group (CCDAN) (see Collaborative Review Group Search Strategy). Reference lists of related reviews and references of located studies. Contact was made with authors working in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised, placebo controlled trials using antidepressants in the treatment of the presenting episode of depression in patients described as elderly, geriatric senile or older adult.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two types of data were extracted (if available) from each study. The first type of data was dichotomous data, this consisted of recovered/not recovered. The second, continuous data,included: Hamilton Depression Rating Scale (HAM-D), Montgomery-Asberg Rating Scale (MADRS) and other depression rating scale scores. An analysis using Peto Odds ratios for the dichotomous data and weighted mean difference for continuous data was performed using RevMan 3.1. The presence of heterogeneity of treatment effect was assessed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Seventeen trials contributed data to the analyses comparing the efficacy of antidepressant treatment and placebo. Analyses of efficacy were based on 245 patients treated with Tricyclic antidepressants (223 with placebo), 365 patients treated with SSRIs (372 with placebo) and 58 patients treated with MAOIs (63 with placebo). The results using a fixed effect model, for the three groups respectively were, TCAs; OR: 0.32 (95% CI: 0.21,0.47), SSRIs; OR; 0.51 (95% CI: 0.36,0.72), MAOIs: OR 0.17 (95% CI: 0.07,0.39).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>TCAs, SSRIs and MAOIs are effective in the treatment of older community patients and inpatients likely to have severe physical illness. At least six weeks of antidepressant treatment is recommended to achieve optimal therapeutic effect. There is little evidence concerning the efficacy of low dose TCA treatment. Further trials are required before low dose TCA treatment is routinely recommended.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-01 12:43:38 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Approximately ten percent of people over the age of 60 suffer from depression to the degree that warrants intervention (<LINK REF="REF-Saunders-1993" TYPE="REFERENCE">Saunders 1993</LINK>). Community studies have demonstrated that older depressed men are three times more likely to die and depressed women twice as likely to die compared to non depressed controls (<LINK REF="REF-Davidson-1988" TYPE="REFERENCE">Davidson 1988</LINK>). It is also acknowledged that relatively few depressed older adults receive therapeutic interventions. Those that do are likely to receive low dose antidepressant treatment (<LINK REF="REF-Wilson-1999" TYPE="REFERENCE">Wilson 1999</LINK>).</P>
<P>Depression in later life is thought to differ from depression in younger subjects in aspects of aetiology, presentation, treatment and outcome (<LINK REF="REF-Schneider--1995" TYPE="REFERENCE">Schneider 1995</LINK>). Depression in older people often complicates, or is obscured by co-morbid physical illness. The depressive syndrome should be viewed in the context of increasing social, physical and neurophysiological diversity associated with the ageing process (<LINK REF="REF-Rabbitt-1993" TYPE="REFERENCE">Rabbitt 1993</LINK>). These include frequently experienced changes in immediate social structures, loss of neurological resilience, lowered threshold of cortical arousal, decompensation in homeostatic processes (<LINK REF="REF-Gold-1988" TYPE="REFERENCE">Gold 1988</LINK>) and concomitant physical illness. All are identified as potential vulnerability factors for depression. As a consequence drug treatment of older, depressed patients is often carried out in institutions and hospitals on patients suffering from multiple physical illness and handicap. </P>
<P>It is evident that older patients are more prone to side effects and experience greater difficulty in tolerating dosages that are of therapeutic efficacy (<LINK REF="REF-Schneider--1995" TYPE="REFERENCE">Schneider 1995</LINK>). They may respond to lower dosage as a consequence of changes in metabolic rate and shifts in the body fat ratio associated with the ageing process. Physical illness and handicap are associated with poor outcome and may influence the efficacy and tolerability of antidepressant treatment. Lastly, there is a growing body of literature indicating that older subjects may require longer to respond to antidepressant medication than younger subjects (<LINK REF="REF-Reynolds-1996" TYPE="REFERENCE">Reynolds 1996</LINK>). </P>
<P>It is acknowledged that the definition of an 'older person' presents problems throughout psychogeriatric research (<LINK REF="REF-Schneider--1995" TYPE="REFERENCE">Schneider 1995</LINK>). We have limited our study to those trials that include older patients described as such, or when not described those trials in which all the patients are over the age of 60, with view to addressing the aforementioned issues.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To conduct a review, testing the hypothesis that antidepressants are more effective than placebo in the treatment of depression in older patients.</P>
<P>To identify the duration of treatment required to achieve optimum therapeutic advantage of antidepressant compared to placebo in older patients.</P>
<P>To examine the efficacy of low dose antidepressant treatment in older patients</P>
<P>To test the hypothesis that antidepressants are effective treatment (compared to placebo) in the treatment of older, institutionalised and hospitalised patients likely to suffer from physical illness and handicap.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-01 12:43:38 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>The review will include all randomised, placebo controlled trials using antidepressant drugs in the treatment of depression in subjects described as elderly, geriatric, senile and older adults or in trials where all subjects are over the age of 60. Trials that include subjects under the age of 60 will be excluded unless data concerning subjects over the age of 60, or those described as elderly, geriatric or senile, were randomised and analysed separately.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Diagnoses: Patients are included in the review if diagnosed as suffering from depression (major or minor) by any criteria. Patients suffering from other mental illnesses will be excluded from the review. The review will include patients suffering from concomitant physical illness. Trials including patients with an explicit diagnosis of dementia have been excluded.<BR/>Gender: Included trials will involve subjects of either sex. <BR/>Age: Our review will accept studies that include subjects described as elderly, geriatric senile, or older adults or in trials where all subjects are over the aged 55 and over.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The review will include all randomised, placebo controlled trials using antidepressant drug treatments. Trials that randomise subjects into receiving more than one antidepressant simultaneously were excluded, as were trials that examine the prophylactic efficacy of antidepressant treatment and those that include formal psychotherapeutic treatments.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcome measure used in this review is the trialists' dichotomous outcome of recovered versus not recovered. This is determined by the number of patients in each group that have shown significant clinical improvement at the end of the trial. This is based on either a change in score of a set amount or achieving a predetermined score, at or below a cut off point on the Hamilton Depression Rating Scale (HAM-D) (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>), Clinical Global Impression (CGI) scale or other rating scale. The secondary outcome included analyses of continuous data from rating scales.</P>
<P>Only one study (<LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK>) measured quality of life using the Short Form 36 (SF36) (<LINK REF="REF-Ware-1992" TYPE="REFERENCE">Ware 1992</LINK>). </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-01 12:43:38 +0000" MODIFIED_BY="[Empty name]">
<P>A two-stage search strategy was adopted due to the difficulty in locating trials in older patients. In the first stage we validated the electronic search strategy. The abstracts of all trials that were held on the Cochrane Collaboration Depression, Anxiety and Neurosis (CCDAN) register some 7000 abstracts, were read by two reviewers with the intent to identify all trials in older depressed people. When abstracts failed to characterise the trial population sufficiently, the full article was examined. An electronic search strategy was devised that identified all the relevant articles identified through the above procedure.</P>
<P>This produced the following electronic search strategy:</P>
<P>Elder*<BR/>Geriatri*<BR/>Senil*<BR/>Older<BR/>Old Age<BR/>Late Life<BR/>Aged, 80-And-Over<BR/>Combined with (AND)<BR/>(Depress* OR Dysthymi*) AND #30 = Pharmacotherapy</P>
<P>(1) Electronic bibliographic databases<BR/>Computer-assisted searches were undertaken of the following electronic databases: PsycLIT; MEDLINE; EMBASE; CINAHL.</P>
<P>The optimal sensitive search strategy of the Cochrane Collaboration for randomised controlled trials (refer Cochrane Handbook, 1996) was used in conjunction with search terms identified above.</P>
<P>The following databases were searched using the CCDAN Trials Register search strategy (see CCDAN Review Group).<BR/>PsycLIT (1887-1999)<BR/>MEDLINE (1966-1999)<BR/>EMBASE (1982-1999)<BR/>LILACS (1982-1999)<BR/>CINAHL (1982-1999)<BR/>SIGLE (19---1999)<BR/>Psyndex (1977-1999)<BR/>National Research Register (1999)<BR/>Dissertation Abstracts International<BR/>Biological Abstracts</P>
<P>(2) The Cochrane Controlled Trials Register and the Cochrane Collaboration Depression Anxiety and Neurosis Controlled Trials Register were searched using the search terms.<BR/>(3) Hand-searching</P>
<P>Additional hand searching of conference abstract and citation lists was undertaken. The International Journal of Geriatric Psychiatry (1989-1999) The Irish Journal of Psychological Medicine (1996-1999) and The American Journal of Orthothpsychiatry (1970-1999) were hand searched.</P>
<P>Six hundred and ninety seven citations concerning older people were identified from the CCDAN database. Of these 366 results concerned depression and the abstracts were assessed for inclusion into the review.</P>
<UL>
<LI>71 articles were excluded as they were not studies on elderly populations.</LI>
</UL>
<UL>
<LI>57 articles were excluded as they were not studying a depressed population or the population included patients with other psychiatric disorders e.g. dementia, alcoholism, bipolar affective disorder.</LI>
<LI>88 articles were excluded as they reported trials that were not placebo controlled.</LI>
</UL>
<UL>
<LI>16 articles were excluded as they reported on trials that were of continuation or maintenance antidepressant treatment.</LI>
</UL>
<UL>
<LI>14 articles were excluded as they were reporting either dose response trials or trials using a combination of drugs</LI>
</UL>
<UL>
<LI>1 article was excluded as it was a literature review</LI>
</UL>
<UL>
<LI>11 articles were excluded as they were reporting trials on electro convulsive therapy (ECT), prevalence studies, prescribing practice or risk factors for depression.</LI>
</UL>
<P>This left 108 articles that were included at this stage. Full papers were obtained and read to assess for inclusion.</P>
<P>Additional searching of citation lists identified 78 articles of which 5 were included in the review</P>
<P>The search strategy generated 23 placebo-controlled trials eligible for entry into the review.</P>
<P>However 6 of these failed to provide extractable data:<BR/>Branconnier (1982)<BR/>Branconnier (1983)<BR/>Jansen (1984)<BR/>Schwiezer (1994)<BR/>Sunderland (1994)<BR/>Wallace (1995)</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Three reviewers independently assessed the relevance of each trial, blind to decision made by each other (KW, PM, AS). Each trial was assessed against pre-set criteria and rated on a scoring sheet. In cases of disagreement decisions were reached by consensus through open discussion. Reasons for exclusion and /or inclusion were recorded. Two reviewers were acknowledged experts in the field. Reviewers were blind to authorship of trials, journals and institutions from which citations come. Blindness was tested through reviewer's 'best guessing' authorship, journal and institution. Data were extracted from selected trials and further information requested from authors when insufficient data was available. In trials that examined the efficacy of more than one drug against placebo, drug treatments were considered independent of one another and analysed separately.</P>
<P>Data Collection:<BR/>Data were extracted from each study, using a pre-designed form. Data was entered on a Microsoft database and subsequently onto RevMan 3.1 statistical software.</P>
<P>Statistical analyses: In undertaking this meta-analyses we have 'lumped' studies together which use the same class, as defined by the British National Formulary (BNF), September 1999 (the BNF is a publication authorised by the United Kingdom Joint Formulary Committee) of antidepressants (<LINK REF="REF-BMA-1999" TYPE="REFERENCE">BMA 1999</LINK>). Those antidepressants that do not readily fall into specific classes are divided into those that the BNF categorises as antidepressants and those that are not. The main outcome measures included the odds ratios and 95% confidence intervals and pooled estimates using Peto method. Continuous data was pooled by calculating the weighted mean difference (WMD), where studies have used the same instruments. When difference scales have been used the standardised mean differences has been used. Discontinuation rates were identified and reported where possible.</P>
<P>Study quality:<BR/>Concealment of randomisation was the main quality criteria. The was measured using the Schultz scale (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Studies were given a quality rating from A = trial that were reported to have taken adequate measures to conceal allocation; B = no adequate details about how the randomisation procedure was carried out; C = inadequately concealed (e.g. via alternation or reference to an open random number table).</P>
<P>Data synthesis: <BR/>The primary outcome measure was the dichotomous 'recovered vs not recovered' using the trialists' own criteria, an analysis using the Peto odds ratio was conducted (<LINK REF="REF-Sackett-1997" TYPE="REFERENCE">Sackett 1997</LINK>) using Review Manager 3.1 software. The secondary outcome used weighted mean difference using Review Manager 3.1 software. Heterogeneity of treatment effect was assessed using the Q statistic which approximates the chi square statistic with n - 1 degrees of freedom (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). A fixed effect model was used as the primary analyses, if substantial heterogeneity was found, random effects model was used for the analysis.</P>
<P>We anticipated that the outcome of trials might be influenced by variables other than drug vs placebo. We examined outcomes by recruitment source. Trials were categorised by recruitment of patients from hospital inpatient wards and nursing homes and those recruiting from the community, though outpatient services or volunteers. Meta analysis was also conducted on trials using low dose antidepressant treatment (defined by BNF recommendations). The duration of trial was grouped by duration of post randomisation phase. Lastly, we examined the efficacy of antidepressant treatment in those patients diagnosed as suffering from major depressive disorder.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Twenty-three trials fulfilled the inclusion criteria. Of these, 17 provided sufficient data of acceptable quality to be used in the meta-analyses. The 17 trials generated 45 publications. Of these 53% were sponsored by industry, 18% non-commercial sponsors and 29% unknown sponsorship.</P>
<P>Class of Drug<BR/>Trials were grouped by class of drug as defined by BNF and when not classified by the BNF, drugs were allocated to the pharmacological class to which they were most similar. The principle classes of drugs identified were;</P>
<P>Tricyclic and related antidepressants (TCAs): Nortriptyline, Imipramine, Doxepin, Viloxazine, Lofepramine, and Trazadone. Not included in the BNF: Nomifensine, Diclofensin </P>
<P>Selective serotinergic re-uptake inhibitors and related antidepressants (SSRIs): Fluoxetine</P>
<P>Monoamine oxidase inhibitors and related antidepressants (MAOIs): Phenelzine and Moclobemide (reversible monoamine oxidase inhibitor).</P>
<P>Atypical Antidepressants: Mirtazepine. (not included in the BNF) Minaprine and Medifoxamine.</P>
<P>Drugs not classed as antidepressants by the BNF; Alprazolam, Bupropion. This was not entered into the meta analysis (data is provided in additional information table).</P>
<P>Twelve trials used TCA versus placebo. Two trials used SSRIs versus placebo. Two trials used MAOI versus placebo. Three trials used other antidepressants versus placebo and two trials used drugs not classed as antidepressants. </P>
<P>Trial design<BR/>All trials are of parallel group design. Subjects are randomly assigned to treatment/placebo groups. Seven studies include more than one trial drug, tested against placebo: Three trials use imipramine to compare against placebo and a drug of the same class; (<LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK>; <LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK>; <LINK REF="STD-Gerner-1980-a" TYPE="STUDY">Gerner 1980 a</LINK>). Four studies compare drugs of different pharmacological classes with placebo (<LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK>; <LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>; <LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>; <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK>). The remaining trials compare a single drug against placebo.</P>
<P>Where two drugs from the same class are compared in the same study, only one appears in the meta-analyses (appearing twice in analysis of class would over represent the placebo group). This occurs in three trials. C<LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK> and <LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK> compare imipramine with nomifensine (TCAs) against placebo. Data concerning nomifensine were excluded. Trazadone data from the <LINK REF="STD-Gerner-1980-a" TYPE="STUDY">Gerner 1980 a</LINK> is used at the expense of the imipramine data.</P>
<P>Age Range<BR/>Trials describing patients as elderly, geriatric, senile or older adult, used different minimum ages for this group, however all patients in the analysis are aged 55 or over. Three studies include patients aged 55 and over (<LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK>; <LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>; <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK>). Three studies selected subjects aged 60 and over: (<LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK>; <LINK REF="STD-Jansen-1982" TYPE="STUDY">Jansen 1982</LINK>; <LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK>). In eight studies the mean age of the study sample is between 60 and 69 years old (inclusive): (<LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK>; <LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK>; <LINK REF="STD-Gerner-1980-a" TYPE="STUDY">Gerner 1980 a</LINK>; <LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>; <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK>; <LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK>; <LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>; <LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK>). Five studies have samples with mean ages between 70 and 79 (inclusive): (<LINK REF="STD-Beutler-1987" TYPE="STUDY">Beutler 1987</LINK>; <LINK REF="STD-De-Leo-1984" TYPE="STUDY">De Leo 1984</LINK>; <LINK REF="STD-Jansen-1982" TYPE="STUDY">Jansen 1982</LINK>; <LINK REF="STD-Lakshmanan-1986" TYPE="STUDY">Lakshmanan 1986</LINK>; <LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK>). The remaining four studies (<LINK REF="STD-Hammond-1993" TYPE="STUDY">Hammond 1993</LINK>, <LINK REF="STD-Katz-1990-a" TYPE="STUDY">Katz 1990 a</LINK>; <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK>; <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK>) have samples with mean ages of 80 and over. Three studies include subjects aged 90 and over: (<LINK REF="STD-Gerner-1980-a" TYPE="STUDY">Gerner 1980 a</LINK>; <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK>; <LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>).</P>
<P>Diagnoses, measurement and severity of depression.<BR/>Seven trials employ the Diagnostic and Statistical Manual Research Criteria (DSM 111R) for depression: (<LINK REF="STD-Beutler-1987" TYPE="STUDY">Beutler 1987</LINK>; <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK>; <LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>; <LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK>; <LINK REF="STD-De-Leo-1984" TYPE="STUDY">De Leo 1984</LINK>; <LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>; <LINK REF="STD-Katz-1990-a" TYPE="STUDY">Katz 1990 a</LINK>). Research Diagnostic Criteria (RDC) are used in five studies; (<LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK>; <LINK REF="STD-Gerner-1980-a" TYPE="STUDY">Gerner 1980 a</LINK>; <LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK>; <LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK>; <LINK REF="STD-Jansen-1982" TYPE="STUDY">Jansen 1982</LINK>). The remaining studies use a variety of classification systems: <LINK REF="STD-Hammond-1993" TYPE="STUDY">Hammond 1993</LINK> GMS/AGECAT (Geriatric Mental State/Automated Geriatric Examination for Computer Assisted Taxonomy), <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK> 'structured clinical diagnoses'. <LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK> employed the International Classification of Diseases Issue 9 (ICD 9), 309.1 definition of prolonged depressive disorder. Two studies use rating instrument cut-off scores as sole depression criteria; <LINK REF="STD-Katz-1990-a" TYPE="STUDY">Katz 1990 a</LINK> uses a cut-off score of 18 on the Hamilton Depression Rating Scale (HAM-D (21)) and <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK> employs the Geriatric Depression Scale (GDS) cut-off of 15. <LINK REF="STD-Lakshmanan-1986" TYPE="STUDY">Lakshmanan 1986</LINK> and <LINK REF="STD-Jansen-1982" TYPE="STUDY">Jansen 1982</LINK> do not specify inclusion diagnostic criteria.</P>
<P>In addition to diagnostic criteria, eight studies require a severity of 18 on the HAM-D rating scale. Of the remaining studies; <LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK> and <LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK> employ an HAM-D score of 16 and <LINK REF="STD-De-Leo-1984" TYPE="STUDY">De Leo 1984</LINK> and <LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK> uses an HAM-D score of 20. <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK> uses a GDS score of 15 and <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK> uses a Montgomery-Asberg Depression Rating Scale (MADRS) score of 20. Evans (1997) uses an ELDRS (Evans Liverpool Depression Rating Scale) cut off score of five as a preliminary screening instrument prior to conducting a diagnostic interview using the GMS/AGECAT. <LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK> entered patients with ECP score (Evaluation Clinique de la Personnalite) between 53 and 104. <LINK REF="STD-Jansen-1982" TYPE="STUDY">Jansen 1982</LINK> does not employ rating scale entry criteria. </P>
<P>Outcome Measures<BR/>Few trials used outcome measures other than change in depression scores and recovery/non recovery. Thirteen of the 17 used change in the 17, 21 or 24 version of the HAM-D as the primary outcome measurement. Only three studies did not include the HAM-D as an outcome measure (primary or secondary). The remaining four used change in a variety of scales; <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK> Geriatric Depression Scale, <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK> the MADRS, <LINK REF="STD-De-Leo-1984" TYPE="STUDY">De Leo 1984</LINK> used the Zung Self Assessment Rating Scale and <LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK> used changes in the Evaluation Clinique de la Personnalite (ECP) as a main outcome measure. Fifteen studies used the dichotomised outcome of recovered/non recovered. Of these, nine used a reduction in the HAM-D and the other six used the CGI score.</P>
<P>Study size<BR/>There are five multicentre studies included in the review (<LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK>; <LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK>; <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK>; <LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>; <LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK>). The remainder are single centre studies. Four studies had 50 (in one case; 48 in one arm) or more subjects randomised to each study arm (<LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>; <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK>; <LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK>; <LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK>). Three studies have between 30 and 49 (inclusive) subjects allocated to each experimental arm (<LINK REF="STD-Hammond-1993" TYPE="STUDY">Hammond 1993</LINK>; <LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>; <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK>). The ten remaining trials included in the review have less than 30 subjects allocated to each experimental arm (<LINK REF="STD-Beutler-1987" TYPE="STUDY">Beutler 1987</LINK>; <LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK>; <LINK REF="STD-De-Leo-1984" TYPE="STUDY">De Leo 1984</LINK>; <LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK>; <LINK REF="STD-Gerner-1980-a" TYPE="STUDY">Gerner 1980 a</LINK>; <LINK REF="STD-Jansen-1982" TYPE="STUDY">Jansen 1982</LINK>; <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK>; <LINK REF="STD-Katz-1990-a" TYPE="STUDY">Katz 1990 a</LINK>; <LINK REF="STD-Lakshmanan-1986" TYPE="STUDY">Lakshmanan 1986</LINK>; <LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK>).<BR/> <BR/>Duration of trials<BR/>Trials were classified by duration of the post randomisation double blind phase. <LINK REF="STD-Beutler-1987" TYPE="STUDY">Beutler 1987</LINK> is the longest study (20 weeks/ 140 days). The long duration can be explained by a three-month follow-up assessment and the increased time required for psychotherapeutic intervention in two of the experimental arms (excluded from this review). One study (<LINK REF="STD-Hammond-1993" TYPE="STUDY">Hammond 1993</LINK>) had a duration of 8 weeks (56 days). Four studies have duration of seven weeks (49 days) (<LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK>; <LINK REF="STD-Katz-1990-a" TYPE="STUDY">Katz 1990 a</LINK>; <LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>; <LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK>). Three studies have duration of 6 weeks (42 days) (<LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>; <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK>; <LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK>). <LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK> has a duration of five weeks (35 days). Five studies have duration of four weeks (28 days) (<LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK>; <LINK REF="STD-De-Leo-1984" TYPE="STUDY">De Leo 1984</LINK>; <LINK REF="STD-Gerner-1980-a" TYPE="STUDY">Gerner 1980 a</LINK>; <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK>; <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK>). Two studies have a duration of 3 weeks (21 days) (<LINK REF="STD-Jansen-1982" TYPE="STUDY">Jansen 1982</LINK>; <LINK REF="STD-Lakshmanan-1986" TYPE="STUDY">Lakshmanan 1986</LINK>). Meta-analyses were conducted on groups of trials (defined by duration) with 50 or more patients randomised to each experimental arm. </P>
<P>Recruitment source and patient exclusions</P>
<P>Patients with an explicit diagnosis of dementia were excluded from the study. The <LINK REF="STD-Hammond-1993" TYPE="STUDY">Hammond 1993</LINK> study included patients with a Mini Mental state Score (MMSE) of 10 or more. <LINK REF="STD-Katz-1990-a" TYPE="STUDY">Katz 1990 a</LINK>; <LINK REF="STD-Lakshmanan-1986" TYPE="STUDY">Lakshmanan 1986</LINK>; <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK> included some patients with mild to moderate cognitive impairment (MMSE &lt;20). <LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK> excluded those with moderate to severe dementia, <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK> excluded severe cases of dementia, <LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK> excluded those with MMSE score of less than 24 and <LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK> excluded patients with scores &lt;25. the remaining studies excluded dementia sufferers (<LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>; <LINK REF="STD-Jansen-1982" TYPE="STUDY">Jansen 1982</LINK>; <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK>; <LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>) or did not specify (<LINK REF="STD-Beutler-1987" TYPE="STUDY">Beutler 1987</LINK>; <LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK>; <LINK REF="STD-De-Leo-1984" TYPE="STUDY">De Leo 1984</LINK>; <LINK REF="STD-Gerner-1980-a" TYPE="STUDY">Gerner 1980 a</LINK>; <LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK>). Most excluded patients with 'significant' or 'unstable' medical conditions. However such terms are open to interpretation and there is considerable variability across trials. A minority of trials excluded patients with unstable epilepsy, convulsions and alcohol or drug dependency. </P>
<P>Trials were grouped by source of recruitment: two trials did not provide information concerning recruitment source (<LINK REF="STD-De-Leo-1984" TYPE="STUDY">De Leo 1984</LINK>; <LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>) and one trial had mixed nursing home and sheltered accommodation patients (<LINK REF="STD-Katz-1990-a" TYPE="STUDY">Katz 1990 a</LINK>). Six trials recruited from hospital inpatient unit and rehabilitation units (<LINK REF="STD-Hammond-1993" TYPE="STUDY">Hammond 1993</LINK>; <LINK REF="STD-Jansen-1982" TYPE="STUDY">Jansen 1982</LINK>; <LINK REF="STD-Lakshmanan-1986" TYPE="STUDY">Lakshmanan 1986</LINK>; <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK>; <LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK>; <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK>). Two of these trials (<LINK REF="STD-Hammond-1993" TYPE="STUDY">Hammond 1993</LINK>; <LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK>) were conducted on physically ill geriatric patients. Exclusion criteria included hepatic insufficiency, glaucoma, urinary and prostate problems, conductive cardiac conditions and epilepsy. The exclusion criteria reflect the possible complications imposed by the trial drug: Lastly patients requiring Electro Convulsive Therapy (ECT), or severely agitated, suffering from bipolar affective disorder, alcohol dependency or schizophrenia were excluded. Despite a large number of patients being excluded from these studies, most included patients had severe and multiple physical illnesses. </P>
<P>Of the remaining studies included in the review; eight studies were conducted on outpatients or volunteers. It is safe to assume that the majority of these patients are mobile, living relatively independently in the community. In particular, two studies recruited patients through advertisement as well as through outpatient clinics (<LINK REF="STD-Beutler-1987" TYPE="STUDY">Beutler 1987</LINK>; <LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>)). These trials tended to exclude patients with suicidal ideas, physical illness and alcohol abuse. Only three indicate the number of excluded patients that fulfilled the depression inclusion criteria. Twenty of 84 potential patients (24%) were excluded in the <LINK REF="STD-Beutler-1987" TYPE="STUDY">Beutler 1987</LINK> study, 47 of 137 potential patients (34%) were excluded in the <LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK> trial, seven of the potential 51 (14%) were excluded in <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK> trial and seven (5%) were excluded from <LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK> trial. </P>
<P>Low dosage antidepressant trials:<BR/>Two of studies examined the efficacy of low dose tricyclic treatment: <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK> compared 70 mgs daily of lofepramine and <LINK REF="STD-Lakshmanan-1986" TYPE="STUDY">Lakshmanan 1986</LINK>; 10-20 mgs daily of doxepin with placebo. Both studies were conducted on small numbers of inpatients. <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK> compared low dose (150 mgs) and high dose bupropion to placebo on an outpatient population. All other trials examined drugs described by the BNF were within the included guidelines.</P>
<P>Discontinuation<BR/>Meta analysis of discontinuation rates was conducted by class of antidepressant. Discontinuation indicates all patients that were removed from the post randomisation phase. A wide variety of reasons were provided for removing patients. These included death, non-compliance emergent physical illness, intolerance of side effects and loss to follow-up.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Description of concealment of allocation was rated as B in all studies, no adequate details about how the randomisation procedure was carried out. We are currently contacting the trialists to gather further information and will update the review with this information.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Seventeen trials met our inclusion criteria and provided data suitable for use in the analyses.</P>
<P>Efficacy<BR/>Tricyclic Antidepressants<BR/>Eleven trials contributed to the efficacy data concerning TCAs. Ten of these contributed dichotomous data: recovered/not recovered. One trial contributed continuous data (<LINK REF="STD-Lakshmanan-1986" TYPE="STUDY">Lakshmanan 1986</LINK>) and one trial contributed both (<LINK REF="STD-Katz-1990-a" TYPE="STUDY">Katz 1990 a</LINK>). </P>
<P>The analyses of the dichotomous data gives an estimated pooled fixed effect Odds Ratio of 0.32 (CI 0.21, 0.47); Q statistic 14.7194, df:=9, p=0.989. The numbers needed to treat (NNT) is 3.97 (CI 3.88, 4.05), implying that approximately four patients would need to be treated to produce one that recovers that would not have done so if given placebo. Only one trial provided continuous data using the HAM-D, however, three trials (active drug N=50, placebo N=52, one of which was low dose treatment) provided continuous data using the CGI; WMD; -2.907 (-5.489, -3.24). </P>
<P>Selective Serotonin Reuptake Inhibitors<BR/>Two trials included in the analyses used fluoxetine. <LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK> examined its efficacy in a large multi-centred study of community patients and <LINK REF="STD-Hammond-1993" TYPE="STUDY">Hammond 1993</LINK> recruited from severely physically ill, medical inpatients. The later study was considerably smaller, possibly effecting the power of the study (type two error). Analyses of the two studies gives an estimated pooled effect and random effect odds ratio of 0.51 (CI 0.36, 0.72): Q statistic 0.1784, df=1, P=0.6727. This gives a numbers needed to treat of 8.45 (CI 8.38, 8.53). This implies that approximately eight patients would need to be treated with an SSRI to produce one recovery from depression that would not have happened if treated with placebo alone.</P>
<P>Monoamine Oxidase Inhibitors<BR/>The analyses consisted of two trials of two different MAOIs; moclobemide (<LINK REF="STD-Nair-1995" TYPE="STUDY">Nair 1995</LINK>) and Phenelzine (<LINK REF="STD-Georgotas-1986" TYPE="STUDY">Georgotas 1986</LINK>). Fifty-eight patients were treated with a MAOI and 63 with placebo. The estimated pooled fixed effect odds ratio is 0.17 (CI 0.07, 0.39): Q statistic 1.01, df=1, P=0.3149. This generates a number needed to treat of 3.14 (CI 2.99,3.29), suggesting that approximately three patients would need to be treated to get one better that would not have done so if given placebo, however this is based on small numbers.</P>
<P>Atypical antidepressants<BR/>Three studies were included, examining different drugs of different pharmacological classes: Minaprine (<LINK REF="STD-Parnetti-1991" TYPE="STUDY">Parnetti 1991</LINK>), providing continuous data and Mitrazepine (<LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>) and Medifoxamine (<LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK>) providing dichotomous data. Analyses of pooled, dichotomous data showed significant effect compared to placebo, generating an Odds ratio of 0.52 (CI 0.29, 0.93) and a numbers needed to treat of 6.63 (CI 6.5, 6.7). </P>
<P>Drugs not classified as antidepressants<BR/>The two trials examining the efficacy of non-antidepressants (<LINK REF="STD-Beutler-1987" TYPE="STUDY">Beutler 1987</LINK>, examining alprazolam and <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK>, examining Bupropion) were not included in the meta-analyses. Data from these trials appears in 'Other data'.</P>
<P>The effect of length of trial<BR/>Trails were classified according to length of the double blind placebo phase. The following groups were generated: 28 days (<LINK REF="STD-Cohn-1984-b" TYPE="STUDY">Cohn 1984 b</LINK>; <LINK REF="STD-De-Leo-1984" TYPE="STUDY">De Leo 1984</LINK>; <LINK REF="STD-Gerner-1980-a" TYPE="STUDY">Gerner 1980 a</LINK>; <LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK>) 35 (<LINK REF="STD-Merideth-1984" TYPE="STUDY">Merideth 1984</LINK>), 42 (<LINK REF="STD-Halikas-1995" TYPE="STUDY">Halikas 1995</LINK>; <LINK REF="STD-Meignan_x002d_Debray-1990" TYPE="STUDY">Meignan-Debray 1990</LINK>; <LINK REF="STD-Tollefson-1993" TYPE="STUDY">Tollefson 1993</LINK>) 56 days (<LINK REF="STD-Hammond-1993" TYPE="STUDY">Hammond 1993</LINK>). They were analysed using dichotomous outcome data (recovery/non recovery). Three groups of trials had more than 50 represented in each arm 28 days, 42 days and 49 days. All three groups of trials demonstrated significant advantage of active drug over placebo. (28 days OR; 0.40, CI; 0.21, 076; 42 days OR 0.22 CI 0.39,0.71; 49 days OR 0.22 CI 0.12,0.42).</P>
<P>The effect of low dose treatment<BR/>The meta analysis of the two trials (<LINK REF="STD-Lakshmanan-1986" TYPE="STUDY">Lakshmanan 1986</LINK>; <LINK REF="STD-Tan-1994" TYPE="STUDY">Tan 1994</LINK>) demonstrated efficacy of low dose TCA (lofepramine, doxepin) compared to placebo (WMD -2.55 (CI -5.70, -0.40). However only continuous data was available and the sample size (38 receiving active treatment and 15 receiving placebo) was very small. Patients were highly selected and both studies were carried out on inpatients.</P>
<P>Discontinuation rates<BR/>All four antidepressant doses had similar discontinuation rates compared to placebo: TCA OR 0.54 CI 0.21,1.39; SSRI OR 1.06 CI 0.74,1.52; MAOI OR 0.84 CI 0.40,1.75: Atypical OR 0.81 CI 0.41, 1.60.</P>
<P>Recruitment source<BR/>Antidepressants were significantly better than placebo in treating depression in both institutionalised and community recruited patients. The institutionalised patients (153 receiving active drug, 128 receiving placebo) had an OR 0.35 CI 0.21, 0.58;. Community patients (602 received active drug and 468 received placebo) had an OR 0.57 CI 0.35, 0.62.</P>
<P>Depression diagnosis<BR/>The eight trials employing RDC and DSM criteria for Major Depressive Disorder generated 562 patients receiving active treatment and 538 receiving placebo. Antidepressant treatment was more efficacious that placebo (OR: 0.44 CI 0.34, 0.58). Six studies were included in the meta analysis of other types of depression generating 181 patients receiving active drug and 131 receiving placebo. Again, antidepressant treatment was more effective than placebo (OR 0.29 (CI 0.18,0.48).</P>
<P>Quality of life<BR/>Tollefson (1993) was the only study to measure quality of life. Using the SF-36 (<LINK REF="REF-Ware-1992" TYPE="REFERENCE">Ware 1992</LINK>) data for 261 Fluoxetine and 271 Placebo subjects were used. The difference in adjusted mean SF-36 scores for fluoxetine and placebo at end point were analysed. Although some sub-scales were found significant, differences between the groups overall end score, failed to find a significant difference at this end-point analysis. </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. Methodological considerations.<BR/>Only seventeen studies generated data that could be included in the meta-analyses. The majority of these trials excluded large numbers of depressed patients mainly as a consequence of severe depression and physical illness. However those trials that did examine inpatient populations did include patient groups characterised by serious, concomitant physical illness. The 17 trials provided a sample size of less than 2000. The number of different drugs in each class is limited, with only one (fluoxetine) included in the SSRI class. Consequently some caution must be taken in generalising these findings to other drugs of the same class, not included in this review. </P>
<P>Conclusions have to be drawn with some care in view of the small number of patients included in the meta analysis. A number of these studies include patients likely to suffer from dementia. We believe that these represent a minority but are likely to be of greater prevalence in those studies recruiting from inpatient populations. The efficacy of antidepressants in treating depression in dementia sufferers is being reviewed in another Cochrane Review ( <LINK REF="REF-Dening-2000" TYPE="REFERENCE">Dening 2000</LINK>). We acknowledge that recruitment source is a poor substitute for physical illness, handicap and dependency. However, in view of the relative under treatment of depressed older people in institutions we believed it necessary to include this sub analysis. 'Discontinuation rates' include a wide variety of causes of drop out it is wrong to make comparative inference concerning side-effects of different classes of drugs. This issue is being addressed in a subsequent Cochrane review. Attempts to examine how antidepressant dosage and the influence of trial length have been curtailed due to small sample sizes.</P>
<P>2. Quantitative findings.<BR/>All three major antidepressant classes (tricyclics, selective serotonin re-uptake inhibitors and monoamine oxidase inhibitors) appear effective in the treatment of depression in older people when compared to placebo. More trials are required before comment can be made concerning the efficacy of individual antidepressants and other drugs falling outside these groups. In all three major antidepressant classes discontinuation rates were no greater than placebo. Despite the small number of trials it is evident that patients recruited from both institutional settings, likely to have serious concomitant physical illness and those recruited from the community respond to antidepressant treatment. Only three trials examined the efficacy of low dose antidepressants. One (<LINK REF="STD-Kane-1983" TYPE="STUDY">Kane 1983</LINK>) examined the use of bupropion (not classed as an antidepressant) in 18 patients and showed no significant difference from placebo. The other two studies examined doxepin and lofepramine, recruiting a total of 53 patients. Meta-analyses demonstrated significant efficacy (in observer rated scales) when compared to placebo. However the implications of these findings should be viewed with some caution because of the very small numbers involved. Both studies were conducted on inpatients with large numbers having been excluded through strict entry criteria. Lastly, analyses by duration of trial generated three groups that included more than 50 patients allocated to receiving active drug or placebo. Meta-analyses of trials by duration demonstrated significant efficacy of antidepressant compared to placebo from four weeks on.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The main conclusions from this review are <BR/>1. The three major antidepressant classes (TCAs, SSRIs and MAOIs) are effective in the treatment of older people. <BR/>2. Despite the relative under-treatment of older depressed, physically ill and dependant patients in hospitals and nursing homes, antidepressant treatment is effective. <BR/>3. The evidence available indicates that antidepressant treatment of four weeks is likely to have a beneficial effect compared to placebo. However further studies are required before the optimum time to recovery can be determined.<BR/>4. Low dose tricyclic antidepressants may be superior to placebo in the treatment of physically ill inpatients. However, generalisation of these findings must be treated with caution and the clinician should be encouraged to adopt alternative antidepressant treatment strategies until further trials have been conducted. There are no randomised-controlled trials demonstrating the antidepressant efficacy of low dose tricyclics in the treatment of older people in community settings. <BR/>5. There are relatively few placebo-controlled studies examining the efficacy of newer antidepressants in older people. Efficacy information concerning newer drugs has to be inferred from trials conducted in younger patients and those suffering from physical illness. They may take longer to work and be effective in lower doses.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. Further trials are required before low dose tricyclic antidepressant treatment can be recommended. <BR/>2. New antidepressant trials should be subjected to dose response studies in older people.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The review is supported by the Wirral and Cheshire Community (NHS) Trust in collaboration with the University of Liverpool.</P>
<P>We would also like to thank Hugh McGuire Trials Coordinator (UK) of the Depression Anxiety and Neurosis Group for his help.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>K Wilson, Reviewer and main author<BR/>P Mottram, Reviewer, statistics<BR/>A Sivanranthan, Reviewer<BR/>A Nightingale, Search strategy and article retrieval</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>The first draft of this review update has been submitted and is currently undergoing peer review. <BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Beutler-1987" NAME="Beutler 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beutler LE, Scogin F, Kirkish P, Schretlen D, Corbishley A, Hamblin D et al</AU>
<TI>Group cognitive therapy and alprazolam in the treatment of depression in older adults.</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>1987</YR>
<VL>55</VL>
<NO>4</NO>
<PG>550-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohn-1984-b" NAME="Cohn 1984 b" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohn JB, Varga L, Lyford A</AU>
<TI>A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients</TI>
<SO>Journal of Clnical Psychiatry</SO>
<YR>1984</YR>
<VL>45</VL>
<NO>4 Pt 2</NO>
<PG>68-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Leo-1984" NAME="De Leo 1984" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Leo D, Ceola A, Magni G, Renesto V, Pacchioni A</AU>
<TI>Viloxazine in the treatment of depression in the aged. Double-blind placebo study</TI>
<TO>La viloxazina nel trattamento della depressione dell'anziano. Studio in doppio cieco verso placebo</TO>
<SO>Minerva Psichiatrica</SO>
<YR>1984</YR>
<VL>25</VL>
<NO>2</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Leo D, Ceola A, Magni G</AU>
<TI>Viloxazine against placebo in a double-blind study in depressed elderly patients</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1984</YR>
<VL>36</VL>
<NO>2</NO>
<PG>239-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Georgotas-1986" NAME="Georgotas 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Georgotas A, McCue RE, Cooper T, Chang I, Mir P, Welkowitz J</AU>
<TI>Clinical predictors of response to antidepressants in elderly patients</TI>
<SO>Biological Pschiatry</SO>
<YR>1987</YR>
<VL>22</VL>
<NO>6</NO>
<PG>733-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Georgotas A, McCue RE, Cooper TB, Nagachandran N, Friedhoff A</AU>
<TI>Factors affecting the delay of antidepressant effect in responders to nortriptyline and phenelzine</TI>
<SO>Psychiatry Research</SO>
<YR>1989</YR>
<VL>28</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Georgotas A, McCue RE, Friedman E, Cooper TB</AU>
<TI>A placebo-controlled comparison of the effect of nortriptyline and phenelzine on orthostatic hypotension in elderly depressed patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>6</NO>
<PG>413-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Georgotas A, McCue RE, Friedman E, Cooper TB</AU>
<TI>Electrocardiographic effects of nortriptyline, phenelzine, and placebo under optimal treatment conditions</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>144</VL>
<NO>6</NO>
<PG>798-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Georgotas A, McCue RE, Friedman E, Cooper TB</AU>
<TI>Response of depressive symptoms to nortriptyline, phenelzine and placebo</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>151</VL>
<PG>102-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Georgotas A, McCue RE, Hapworth W, Friedman E, Kim OM, Welkowitz J et al</AU>
<TI>Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly</TI>
<SO>Biological Psychiatry</SO>
<YR>1986</YR>
<VL>21</VL>
<NO>12</NO>
<PG>1155-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Georgotas A, McCue RE, Reisberg B, Ferris SH, Nagachandran N, Chang I et al</AU>
<TI>The effects of mood changes and antidepressants on the cognitive capacity of elderly depressed patients</TI>
<SO>International Psychogeriatrics</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>2</NO>
<PG>135-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Georgotas A, Stokes P, McCue RE, Dubow A, Welkowitz J, Friedman E et al</AU>
<TI>The usefulness of DST in predicting response to antidepressants: a placebo-controlled study</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1986</YR>
<VL>11</VL>
<NO>1</NO>
<PG>21-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerner-1980-a" NAME="Gerner 1980 a" YEAR="1380">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gerner R, Estabrook W, Steuer J, Jarvik L</AU>
<TI>Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1980</YR>
<VL>41</VL>
<NO>6</NO>
<PG>216-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerner R, Estabrook W, Steuer J, Waltuch L, Kakkar P, Jarvik L</AU>
<TI>A placebo-controlled double-blind study of imipramine and trazodone in geriatric depression</TI>
<SO>Psychopathology in the Aged</SO>
<YR>1980</YR>
<VL>69</VL>
<PG>167-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hayes RL, Gerner RH, Fairbanks L, Moran M, Waltuch L</AU>
<TI>ECG findings in geriatric depressives given trazodone, placebo, or imipramine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1983</YR>
<VL>44</VL>
<NO>5</NO>
<PG>180-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Halikas-1995" NAME="Halikas 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Halikas JA</AU>
<TI>Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patients</TI>
<SO>Human Psychopharmacology</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>Suppl 2</NO>
<PG>125-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hammond-1993" NAME="Hammond 1993" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Evans M, Hammond M, Wilson K, Lye M, Copeland J</AU>
<TI>Placebo-controlled treatment trial of depression in elderly physically ill patients</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>8</NO>
<PG>817-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans M, Hammond M, Wilson K, Lye M, Copeland J</AU>
<TI>Treatment of depression in the elderly: Effect of physical illness on response</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>12</NO>
<PG>1189-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hammond MF, Evans ME, Lye M</AU>
<TI>Antidepressants and old people</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<NO>8865</NO>
<PG>244-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansen-1982" NAME="Jansen 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jansen W, Bruckner GW, Henauer S, Omer LM</AU>
<TI>Clinical double blind comparison of diclofensine and placebo in geriatric patients with depressive syndromes</TI>
<TO>Klinischer Doppelblindvergleich von Diclofensin und Plazebo bei geriatrischen Patienten mit depressiven Verstimmungszustanden</TO>
<SO>Pharmopsychiatria</SO>
<YR>1982</YR>
<VL>15</VL>
<NO>6</NO>
<PG>205-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-1983" NAME="Kane 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Cole K, Sarantakos S, Howard A, Borenstein M</AU>
<TI>Safety and efficacy of bupropion in elderly patients: preliminary observations</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1983</YR>
<VL>44</VL>
<NO>5 Pt 2</NO>
<PG>134-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katz-1990-a" NAME="Katz 1990 a" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Katz IR, Simpson GM, Curlik SM, Parmelee PA, Muhly C</AU>
<TI>Pharmacologic treatment of major depression for elderly patients in residential care settings</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51</VL>
<NO>Suppl</NO>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lakshmanan-1986" NAME="Lakshmanan 1986" YEAR="19919">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lakshmanan M, Mion LC, Frengley JD</AU>
<TI>Effective low dose tricyclic antidepressant treatment for depressed geriatric rehabilitation patients. A double-blind study</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1986</YR>
<VL>34</VL>
<NO>6</NO>
<PG>421-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meignan_x002d_Debray-1990" NAME="Meignan-Debray 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meignan-Debray S, Forette B, Roger M</AU>
<TI>Double-blind trial of medifoxamine (Cledial ) versus placebo in elderly patients with depressive disorders</TI>
<TO>Etude comparative en double aveugle de la medifoxamine (Cledial) versus placebo chez le sujet age deprime</TO>
<SO>Psychologie Medicale</SO>
<YR>1990</YR>
<VL>22</VL>
<NO>9</NO>
<PG>883-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merideth-1984" NAME="Merideth 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Merideth CH, Feighner JP, Hendrickson G</AU>
<TI>A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1984</YR>
<VL>45</VL>
<NO>4 Pt 2</NO>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nair-1995" NAME="Nair 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nair NP, Amin M, Holm P, Katona C, Klitgaard N, Ng Ying Kin NM et al</AU>
<TI>Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1995</YR>
<VL>33</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ng Ying Kin NM, Klitgaard N, Nair NP, Amin M, Kragh Sorensen P, Schwariz G et al</AU>
<TI>Clinical relevance of serum nortriptyline and 10-hydroxy-nortriptyline measurements in the depressed elderly: a multicenter pharmacokinetic and pharmacodynamic study</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>15</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ng Ying Kin NM, Nair NP, Amin M, Schwartz G, Ahmed SK, Holm P et al</AU>
<TI>The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>42</VL>
<NO>10</NO>
<PG>925-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parnetti-1991" NAME="Parnetti 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parnetti L, Abate G, Aveni Casucci MA, Balestrieri R, Bartorelli L, Cuzzupoli M et al</AU>
<TI>Multicentre, controlled, randomized, double-blind vs placebo study of minaniprine in elderly patients suffering from prolonged depressive reaction</TI>
<TO>Studio multicentrico controllato e randomizzato in doppio cieco di minaprina vs placebo in pazienti anziani affetti da disturbo depressivo su base reattiva</TO>
<SO>Giornale di Gerontologia</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>3</NO>
<PG>103-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Parnetti L, Sommacal S, Morselli-Labate AM, Senin U</AU>
<TI>Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction</TI>
<SO>Drug Investigation</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>4</NO>
<PG>181-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-1994" NAME="Tan 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tan RS, Barlow RJ, Abel C, Reddy S, Palmer AJ, Fletcher AE et al</AU>
<TI>The effect of low dose lofepramine in depressed elderly patients in general medical wards</TI>
<SO>British Journal of Psychopharmacology</SO>
<YR>1994</YR>
<VL>37</VL>
<NO>4</NO>
<PG>321-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan RS</AU>
<TI>Lowering antidepressant dosages in the elderly</TI>
<SO>Clinical Gerontologist</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>1</NO>
<PG>67-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan RS</AU>
<TI>Prescribing less than recommended doses may be acceptable for geriatric patients</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1998</YR>
<VL>46</VL>
<NO>4</NO>
<PG>536</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollefson-1993" NAME="Tollefson 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ackerman DL, Greenland S, Bystritsky A, Small GW</AU>
<TI>Characteristics of fluoxetine versus placebo responders in a randomized trial of geriatric depression</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1997</YR>
<VL>33</VL>
<NO>4</NO>
<PG>707-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beusterien KM, Steinwald B, Ware JE Jr</AU>
<TI>Usefulness of the SF-36 Health Survey in measuring health outcomes in the depressed elderly</TI>
<SO>Journal of Geriatric Psychiatry and Neurology</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>1</NO>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein DJ, Hamilton SH, Masica DN, Beasley CM Jr</AU>
<TI>Fluoxetine in medically stable, depressed geriatric patients: effects on weight</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>5</NO>
<PG>365-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heiligenstein JH, Ware JE Jr, Beusterien KM, Roback PJ, Andrejasich C, Tollefson GD</AU>
<TI>Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression</TI>
<SO>International Psychogeriatrics</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>Suppl</NO>
<PG>125-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koran L, Hertzman M, Meyers B, Holman S, Tollefson G</AU>
<TI>Predicting response to fluoxetine in geriatric patients with DSM-III-R major depression</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1994</YR>
<VL>30</VL>
<PG>76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koran LM, Hamilton SH, Hertzman M, Meyers BS, Halaris AE, Tollefson GD et al</AU>
<TI>Predicting response to fluoxetine in geriatric patients with major depression</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>6</NO>
<PG>421-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS</AU>
<TI>Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>2</NO>
<PG>97-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Small GW, Birkett M, Meyers BS, Koran LM, Bystritsky A, Nemeroff CB</AU>
<TI>Impact of physical illness on quality of life and antidepressant response in geriatric major depression</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1996</YR>
<VL>44</VL>
<NO>10</NO>
<PG>1220-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Small GW, Hamilton SH, Bystritsky A, Meyers BS, Nemeroff CB</AU>
<TI>Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression</TI>
<SO>International Psychogeriatrics</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>Suppl</NO>
<PG>41-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Small GW, Schneider LS, Hamilton SH, Bystritsky A, Meyers BS, Nemeroff CB</AU>
<TI>Site variability in a multisite geriatric depression trial</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>12</NO>
<PG>1089-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Bosomworth JC, Heiligenstein JH, Potvin JH, Holman S</AU>
<TI>A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression</TI>
<SO>International Psychogeriatrics</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>1</NO>
<PG>89-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Holman SL</AU>
<TI>Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression</TI>
<SO>International Journal of Psychopharmacology</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>4</NO>
<PG>253-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Albarede-1983" NAME="Albarede 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Albarede JL, Boye JB, Broutin JM et al</AU>
<TI>Efficacity of nomifensin (Alival) in geriatrics: Multicentric double blind study against a placebo</TI>
<TO>Efficacite de la nomifensine (Alival) en geriatrie: Etude multicentrique en double aveugle contre placebo</TO>
<SO>Revue de Geriatrie</SO>
<YR>1983</YR>
<VL>8</VL>
<NO>4</NO>
<PG>195-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arcand-1993" NAME="Arcand 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arcand M, Hottin P</AU>
<TI>Treatment of depression in the elderly. The use of psychostimulants</TI>
<TO>Le traitement de la depression chez les personnes agees. L'utilite des psychostimulants</TO>
<SO>Canadian Family Physician</SO>
<YR>1993</YR>
<VL>39</VL>
<PG>2420-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ather-1985" NAME="Ather 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ather SA, Ankier SI, Middleton RS</AU>
<TI>A double-blind evaluation of trazodone in the treatment of depression in the elderly</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1985</YR>
<VL>39</VL>
<NO>5</NO>
<PG>192-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balaceanu-1996" NAME="Balaceanu 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Balaceanu-Stolnici C, Covic M, Manoiu A, Vrabiescu M</AU>
<TI>Double blind study concerning the antidepressive effects and the clinical tolerance of Gerovital H-3 without potassium metabisulphate</TI>
<SO>Romanian Journal of Gerontology &amp; Geriatrics</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1-2</NO>
<PG>46-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bella-1990" NAME="Bella 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bella R, Biondi R, Raffaele R, Pennisi G</AU>
<TI>Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>6</NO>
<PG>355-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fulgente T, Onofrj M, Del Re ML, Ferracci F, Bazzano S, Ghilardi MF et al</AU>
<TI>Laevo-acetylcarnitine (Nicetile registered ) treatment of senile depression</TI>
<SO>Clinical Trials Journal</SO>
<YR>1990</YR>
<VL>27</VL>
<NO>3</NO>
<PG>155-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergener-1968-b" NAME="Bergener 1968 b" YEAR="1968">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bergener M, Undeutsch D</AU>
<TI>Methods and problems of clinical psychopharmacology. Results of a double blind study with medazepam and placebo in geriatric psychiatry</TI>
<TO>Methoden und Probleme der klinischen Psychopharmakologie Ergebnisse einer Doppelblindstudie mit Medazepam und Placebo in der Alterspsychiatrie</TO>
<SO>Arzneimittelforschung</SO>
<YR>1968</YR>
<VL>18</VL>
<NO>12</NO>
<PG>1563-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bettini-1994" NAME="Bettini 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bettini R, Ferrari M, Gobbi G, Volanti F, Piccinelli O</AU>
<TI>Clinical and instrumental evaluation of the effect of tiapride in senile involutional syndrome</TI>
<TO>Valutazione clinica e strumentale dell'effetto della tiapride sulla sindrome involutiva senile</TO>
<SO>Clinica Terapeutica</SO>
<YR>1994</YR>
<VL>144</VL>
<NO>3</NO>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohm-1990-a" NAME="Bohm 1990 a" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohm C, Robinson DS, Gammans RE, Shrotriya RC, Alms DR, Leroy A et al</AU>
<TI>Buspirone therapy in anxious elderly patients: a controlled clinical trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>3 Suppl</NO>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bohm C, Robinson DS, Gammans RE</AU>
<TI>Buspirone therapy for elderly patients with anxiety or depressive neurosis</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51</VL>
<NO>7</NO>
<PG>309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonavita-1986" NAME="Bonavita 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bonavita E</AU>
<TI>Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain.</TI>
<SO>International Journal of Clinical Pharmacology, Therapy and Toxicology</SO>
<YR>1986</YR>
<VL>24</VL>
<NO>9</NO>
<PG>511-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branconnier-1981" NAME="Branconnier 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Branconnier RJ, Cole JO, Ghazvinian S, Rosenthal S.</AU>
<TI>Treating the depressed elderly patient: The comparative behavioural pharmacology of mianserin and amitriptyline</TI>
<SO>Typical and atypical antidepressants: Clinical Practice</SO>
<YR>1982</YR>
<ED>Costa E, Racagni G</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Branconnier RJ, Cole JO, Ghazvinian S</AU>
<TI>The therapeutic profile of mianserin in mild elderly depressives</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1981</YR>
<VL>17</VL>
<NO>1</NO>
<PG>129-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branconnier-1983-a" NAME="Branconnier 1983 a" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Branconnier RJ, Cole JO, Ghazvinian S, Spera KF, Oxenkrug GF, Bass JL.</AU>
<TI>Clinical pharmacology of bupropion and imipramine in elderly depressives</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1983</YR>
<VL>44</VL>
<NO>5</NO>
<PG>130-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohn-1990-a" NAME="Cohn 1990 a" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lapierre YD</AU>
<TI>Controlling acute episodes of depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>23-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-1980" NAME="Cooper 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cooper AJ, Datta SR</AU>
<TI>A placebo controlled evaluation of L-tryptophan in depression in the elderly</TI>
<SO>Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie</SO>
<YR>1980</YR>
<VL>25</VL>
<NO>5</NO>
<PG>386-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobie-1992" NAME="Dobie 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dobie RA, Sakai CS, Sullivan MD, Katon WJ, Russo J</AU>
<TI>Antidepressant treatment of tinnitus patients: report of a randomized clinical trial and clinical prediction of benefit</TI>
<SO>American Journal of Otology</SO>
<YR>1993</YR>
<VL>14</VL>
<NO>1</NO>
<PG>18-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fabre-1983" NAME="Fabre 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fabre LF, Brodie HK, Garver D, Zung WW</AU>
<TI>A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1983</YR>
<VL>44</VL>
<NO>5 Pt 2</NO>
<PG>88-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frederiksen-1985" NAME="Frederiksen 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Frederiksen SO, d'Elia G, Bengtsson BO</AU>
<TI>ACTH 4-9 analogue (Org 2766) in depressed elderly patients. I. Effect on depressed mood</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1985</YR>
<VL>72</VL>
<NO>4</NO>
<PG>341-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frederiksen SO, d'Elia G, Bengtsson BO</AU>
<TI>ACTH 4-9 analogue (Org 2766) in depressed elderly patients. II. Effect on memory and vigilance</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1985</YR>
<VL>72</VL>
<NO>4</NO>
<PG>349-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gentili-1984" NAME="Gentili 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gentili P, De Maria F, De Vanna M, Drago F, Omer LM, Ismail S</AU>
<TI>Diclofensine in the treatment of depressed geriatric hospitalized patients: a placebo-controlled double-blind trial</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1984</YR>
<VL>35</VL>
<NO>3</NO>
<PG>386-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansgen-1993" NAME="Hansgen 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hansgen KD, Vesper J, Ploch M</AU>
<TI>Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160</TI>
<SO>Journal of Geriatric Psychiatry and Neurology</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>Suppl 1</NO>
<PG>S15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hebenstreit-1989-b" NAME="Hebenstreit 1989 b" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hebenstreit GF, Fellerer K, Zochling R, Zentz A, Dunbar GC</AU>
<TI>A pharmacokinetic dose titration study in adult and elderly depressed patients</TI>
<SO>Acta Psychiatrica Scandinavica. Supplementum</SO>
<YR>1989</YR>
<VL>350</VL>
<PG>81-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hubner-1993" NAME="Hubner 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hubner WD, Lande S, Podzuweit H</AU>
<TI>Hypericum treatment of mild depressions with somatic symptoms</TI>
<SO>Journal of Geriatric Psychiatry and Neurology</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>Suppl 1</NO>
<PG>S12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jansen-1984" NAME="Jansen 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jansen W, Siegfried K</AU>
<TI>Nomifensine in geriatric inpatients: A placebo-controlled study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1984</YR>
<VL>45</VL>
<NO>4 Pt 2</NO>
<PG>63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarvik-1982-b" NAME="Jarvik 1982 b" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarvik LF, Mintz J, Steuer J, Gerner R</AU>
<TI>Treating geriatric depression: A 26-week interim analysis</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1982</YR>
<VL>30</VL>
<NO>11</NO>
<PG>713-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarvik LF, Read SL, Mintz J, Neshkes RE</AU>
<TI>Pretreatment orthostatic hypotension in geriatric depression: predictor of response to imipramine and doxepin</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>6</NO>
<PG>368-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kivela-1987" NAME="Kivela 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kivela SL, Lehtomaki E</AU>
<TI>Sulpiride and placebo in depressed elderly outpatients: A double-blind study</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1987</YR>
<VL>2</VL>
<NO>4</NO>
<PG>255-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koenig-1989" NAME="Koenig 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koenig HG, Goli V, Shelp F, Kudler HS, Cohen HJ, Meador KG et al</AU>
<TI>Antidepressant use in elderly medical inpatients: lessons from an attempted clinical trial</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>6</NO>
<PG>498-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapierre-1991" NAME="Lapierre 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>EXTRA REF Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM et al</AU>
<TI>Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo</TI>
<SO>Biological Psychiatry</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>9</NO>
<PG>592-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapierre YD</AU>
<TI>Controlling acute episodes of depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>23-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavie-1992" NAME="Lavie 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lavie P, Aharon Peretz J, Klein F, Gruner F, Epstein R, Tzischinsky O et al</AU>
<TI>Sleep quality in geriatric depressed patients: Comparison with elderly demented patients and normal controls and the effects of moclobemide</TI>
<SO>Dementia</SO>
<YR>1992</YR>
<VL>3</VL>
<NO>5-6</NO>
<PG>360-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McNair-1984" NAME="McNair 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McNair DM, Kahn RJ, Frankenthaler LM, Faldetta LL</AU>
<TI>Amoxapine and amitriptyline: II. Specificity of cognitive effects during brief treatment of depression</TI>
<SO>Psychopharmacology</SO>
<YR>1984</YR>
<VL>83</VL>
<NO>2</NO>
<PG>134-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mellow-1990" NAME="Mellow 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mellow AM, Lawlor BA, Sunderland T, Mueller EA, Molchan SE, Murphy DL</AU>
<TI>Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients. Initial experience with a serotonin agonist</TI>
<SO>Biological Psychiatry</SO>
<YR>1990</YR>
<VL>28</VL>
<NO>7</NO>
<PG>588-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Middleton-1975" NAME="Middleton 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Middleton RS</AU>
<TI>A comparison between maprotiline (Ludiomil) and imipramine in the treatment of depressive illness in the elderly</TI>
<SO>Journal of International Medical Research</SO>
<YR>1975</YR>
<VL>3</VL>
<NO>Suppl 2</NO>
<PG>79-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monti-1990" NAME="Monti 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Monti JM, Alterwain P, Monti D</AU>
<TI>The effects of moclobemide on nocturnal sleep of depressed patients</TI>
<SO>Journal of Affective Disorders</SO>
<YR>1990</YR>
<VL>20</VL>
<NO>3</NO>
<PG>201-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nyth-1992" NAME="Nyth 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gottfries CG, Karlsson I, Nyth AL</AU>
<TI>Treatment of depression in elderly patients with and without dementia disorders</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>Suppl 5</NO>
<PG>55-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gottfries CG</AU>
<TI>Depression in the elderly: treatment with selective 5-HT reuptake blockers</TI>
<SO>Psychopharmacology</SO>
<YR>1993</YR>
<VL>111</VL>
<PG>B4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M et al</AU>
<TI>A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1992</YR>
<VL>86</VL>
<NO>2</NO>
<PG>138-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petursson-1993" NAME="Petursson 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petursson H</AU>
<TI>A controlled study of moclobemide in elderly depression with cognitive decline</TI>
<SO>Psychopharmacology</SO>
<YR>1993</YR>
<VL>111</VL>
<PG>B5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roth M, Mountjoy CQ, Amrein R</AU>
<TI>Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>168</VL>
<PG>149-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raffaele-1996" NAME="Raffaele 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Raffaele R, Rampello L, Vecchio I, Tornali C, Malaguarnera M</AU>
<TI>Trazodone therapy of the post-stroke depression</TI>
<SO>Archives of Gerontology and Geriatrics</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>Suppl 5</NO>
<PG>217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reimherr-1990" NAME="Reimherr 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lapierre YD</AU>
<TI>Controlling acute episodes of depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>Suppl 2</NO>
<PG>23-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothblum-1982" NAME="Rothblum 1982" YEAR="1982">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rothblum ED, Sholomskas AJ, Berry C, Prusoff BA</AU>
<TI>Issues in clinical trials with the depressed elderly</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1982</YR>
<VL>30</VL>
<NO>11</NO>
<PG>694-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakalis-1974-a" NAME="Sakalis 1974 a" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sakalis G, Oh D, Gershon S, Shopsin B</AU>
<TI>A trial of Gerovital H-3 in depression during senility</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1974</YR>
<VL>16</VL>
<NO>1</NO>
<PG>59-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schweizer-1994" NAME="Schweizer 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schweizer E, Rickels K, Hassman H, Garcia-Espana F</AU>
<TI>Buspirone and imipramine for the treatment of major depression in the elderly</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>4</NO>
<PG>175-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schweizer E, Rickels K, Hassman H.</AU>
<TI>A double-blind, placebo-controlled comparison of imipramine and buspirone in the treatment of major depression in the elderly in the community</TI>
<SO>Pharmocology Bulletin</SO>
<YR>1994</YR>
<VL>30</VL>
<NO>4</NO>
<PG>639</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siegfried-1986" NAME="Siegfried 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Siegfried K, O'Connolly M</AU>
<TI>Cognitive and psychomotor effects of different antidepressants in the treatment of old age depression</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>1</VL>
<NO>3</NO>
<PG>231-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunderland-1987" NAME="Sunderland 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Newhouse PA, Sunderland T, Tariot PN, Weingartner H, Thompson K, Mellow AM et al</AU>
<TI>The effects of acute scopolamine in geriatric depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<NO>10</NO>
<PG>906-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunderland-1994" NAME="Sunderland 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA et al</AU>
<TI>High-dose selegiline in treatment-resistant older depressive patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>8</NO>
<PG>607-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taeuber-1977" NAME="Taeuber 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Taeuber K</AU>
<TI>Comparison of nomifensine and placebo</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1977</YR>
<VL>4</VL>
<NO>Suppl 2</NO>
<PG>209-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tammaro-1977" NAME="Tammaro 1977" YEAR="1977">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tammaro A, Picceo MT, Gemmellaro P, Bonaccorso O</AU>
<TI>Camazepam versus placebo. A double-blind clinical study on geriatric patients suffering from psychic complaints</TI>
<SO>Arzneimittelforschung</SO>
<YR>1977</YR>
<VL>27</VL>
<NO>11</NO>
<PG>2177-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tiller-1990" NAME="Tiller 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tiller JW</AU>
<TI>Antidepressants, alcohol and psychomotor performance.</TI>
<SO>Acta Psychiatrica Scandinavica, Supplementum</SO>
<YR>1990</YR>
<VL>360</VL>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Truffinet-1990" NAME="Truffinet 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Truffinet P, Rouillon F, Serrurier D, Phillips R</AU>
<TI>Relapses of unipolar depression in the elderly and the efficacy of maprotiline</TI>
<TO>Rechutes de la depression unipolaire chez le sujet age et efficacite de la maprotiline</TO>
<SO>Psychologie Medicale</SO>
<YR>1990</YR>
<VL>22</VL>
<NO>8</NO>
<PG>769-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Knorring-1980" NAME="Von Knorring 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Von Knorring L</AU>
<TI>A double-blind trial: vivalan against placebo in depressed elderly patients.</TI>
<SO>Journal of International Medical Research</SO>
<YR>1980</YR>
<VL>8</VL>
<NO>1</NO>
<PG>18-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wakelin-1986" NAME="Wakelin 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wakelin JS</AU>
<TI>Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data.</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1986</YR>
<VL>1</VL>
<NO>3</NO>
<PG>221-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallace-1995" NAME="Wallace 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wallace AE, Kofoed LL, West AN</AU>
<TI>Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients.</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>6</NO>
<PG>929-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weissman-1992" NAME="Weissman 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weissman MM, Prusoff B, Sholomskas AJ, Greenwald S</AU>
<TI>A double-blind clinical trial of alprazolam, imipramine, or placebo in the depressed elderly</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>3</NO>
<PG>175-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-BMA-1999" NAME="BMA 1999" TYPE="BOOK">
<AU>British Medical Association &amp; Royal Pharmaceutical Society of Great Britain</AU>
<SO>British National Formulary</SO>
<YR>1999</YR>
<EN>38</EN>
<PB>BMA</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cole-1993" NAME="Cole 1993" TYPE="JOURNAL_ARTICLE">
<AU>Cole MG, Primeau FJ</AU>
<TI>Prognosis of delirium in elderly hospital patients</TI>
<SO>CMAJ</SO>
<YR>1993</YR>
<VL>149</VL>
<NO>1</NO>
<PG>41-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davidson-1988" NAME="Davidson 1988" TYPE="JOURNAL_ARTICLE">
<AU>Davidson IA, Dewey ME, Copeland JR</AU>
<TI>The relationship between mortality and mental disorder: Evidence from the Liverpool longitudinal study</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>2</NO>
<PG>95-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dening-2000" NAME="Dening 2000" TYPE="COCHRANE_REVIEW">
<AU>Dening TR, Bains J.</AU>
<TI>Antidepressant drug therapy for depression in people with dementia</TI>
<SO>Cochrane Library</SO>
<YR>2000</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Georgotas-1988" NAME="Georgotas 1988" TYPE="JOURNAL_ARTICLE">
<AU>Georgotas A, McCue RE, Cooper TB, Nagachandran N, Chang I</AU>
<TI>How effective and safe is continuation therapy in elderly depressed patients?</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<NO>10</NO>
<PG>929-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gold-1988" NAME="Gold 1988" TYPE="JOURNAL_ARTICLE">
<AU>Gold PW, Goodwin FK, Chrousos GP</AU>
<TI>Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress</TI>
<SO>New England Journal of Medicine</SO>
<YR>1988</YR>
<VL>319</VL>
<NO>7</NO>
<PG>413-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1996" NAME="Mulrow 1996" TYPE="BOOK">
<AU>Mulrow CD, Oxman AD</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1996</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1988" NAME="Murphy 1988" TYPE="JOURNAL_ARTICLE">
<AU>Murphy E, Smith R, Lindesay J, Slattery J</AU>
<TI>Increased mortality rates in late-life depression</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>152</VL>
<PG>347-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rabbitt-1993" NAME="Rabbitt 1993" TYPE="BOOK_SECTION">
<AU>Rabbitt P</AU>
<TI>Baseline changes in cognitive performance with age</TI>
<SO>Treatment and care in old age psychiatry</SO>
<YR>1993</YR>
<ED>Levy R, Howard R, Burns A</ED>
<PB>Wrightson Biomedical</PB>
<CY>Petersfield</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1996" NAME="Reynolds 1996" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds CF, Frank E, Kupfer DJ, Thase ME, Perel JM, Mazumdar S et al</AU>
<TI>Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>10</NO>
<PG>1288-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sackett-1997" NAME="Sackett 1997" TYPE="BOOK">
<AU>Sackett D</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>1997</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saunders-1993" NAME="Saunders 1993" TYPE="JOURNAL_ARTICLE">
<AU>Saunders PA, Copeland JR, Dewey ME, Gilmore C, Larkin BA, Phaterpekar H et al</AU>
<TI>The prevalence of dementia, depression and neurosis in later life: The Liverpool MRC-APPHA study</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>5</NO>
<PG>838-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider--1995" NAME="Schneider  1995" TYPE="JOURNAL_ARTICLE">
<AU>Schneider LS, Olin JT</AU>
<TI>Efficacy of acute treatment for geriatric depression</TI>
<SO>International Psychogeriatrics</SO>
<YR>1995</YR>
<VL>7</VL>
<NO>Suppl</NO>
<PG>7-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias discussions of methological quality associated with estimates of treatment effect in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ware-1992" NAME="Ware 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ware JE Jr, Sherbourne CD</AU>
<TI>The MOS 36-item short-form health survey (SF-36); 1, Conceptural framework and item selection</TI>
<SO>Medical Care</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>6</NO>
<PG>473-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-1999" NAME="Wilson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wilson KC, Copeland JR, Taylor S, Donoghue J, McCracken CF</AU>
<TI>Natural history of pharmacotherapy of older depressed community residents</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>175</VL>
<PG>439-43</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Beutler-1987">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Analysis: Endpoint<BR/>Duration 20 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Unipolar Major Depression DSMIIIR<BR/>Community and Advert<BR/>N=27<BR/>Sex unknown<BR/>Mean age = 71.6</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=15<BR/>2. Alprazolam N=12<BR/>0.5mg/d to max 0.8mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D<BR/>BDI<BR/>Cognitive Error Questionnaire<BR/>Sleep Efficiency<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Other arms to study Psychotherapy<BR/>N=64 in total<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cohn-1984-b">
<CHAR_METHODS>
<P>RCT Double Blind<BR/>Concealment of allocation unclear<BR/>Analysis: Endpoint<BR/>Duration: 28 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Major Depressive Disorder DSMIII and<BR/>HAM-D &gt; 20<BR/>Outpatients<BR/>N= 63<BR/>Sex 23M, 40F<BR/>Mean age = ~66<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=21<BR/>2. Imipramine N-21<BR/>75mg/d to 200mg/d split dose<BR/>3. Nomifensine N=21<BR/>75mg/d to 200mg/d split dose<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D<BR/>CGI<BR/>Hopkins symptom Checklist<BR/>BPRS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-De-Leo-1984">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 28 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Primary Depression DSMIII<BR/>Symptoms present &gt; 5 months<BR/>Institution for elderly<BR/>N= 46<BR/>Sex 8M, 16F<BR/>Mean age=74.79+9.51<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1 Placebo N=22<BR/>2. Viloxazine N=24<BR/>200mg/d to 300mg/d in split dose<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Zung SDS<BR/>HAM-D<BR/>CGI<BR/>TESS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Georgotas-1986">
<CHAR_METHODS>
<P>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 49 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Major Depression RDC <BR/>HAM-D &gt; 16<BR/>Outpatients (Psych)<BR/>N= 90<BR/>Sex Unknown<BR/>Mean age = 65.7 sd6.8<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=28<BR/>2. Nortriptyline N=25<BR/>Plasma levels 50-180ng/nl<BR/>3. Phenelzine N=22 MAO inhibition &gt;70%<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAMD<BR/>Zung SDS<BR/>CGI<BR/>TESS<BR/>ECG<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Figures given for male/female and age were 75 subjects only</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gerner-1980-a">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 28 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Unipolar Depression RDC<BR/>HAMD &gt;18 <BR/>Outpatients (Psych)<BR/>N=60<BR/>Sex 23M, 37F<BR/>Mean age = 68.4<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=20<BR/>2. Trazodone N=19<BR/>100 - 400mg/d<BR/>3. Imipramine N=21<BR/>50 - 200mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D<BR/>HAMA<BR/>BDI<BR/>TESS<BR/>Effects on cognition ECG<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Halikas-1995">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 42 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Major Depressive Episode DSMIIIR,<BR/>HAMD &gt;18 <BR/>Community &amp; advert recruitment<BR/>N= 150<BR/>Sex 67M, 79F<BR/>Mean Age = ~62<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=50<BR/>2. Mirtazapine N=50<BR/>5mg/d to 35mg/d<BR/>3. Trazodone N=50<BR/>40mg/d to 280mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAMD<BR/>MADRS<BR/>Zung SDS<BR/>CGI<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hammond-1993">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 56 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis GMS Case Level Depression with <BR/>&gt;4 week history <BR/>MMSE &gt;10<BR/>Inpatients (Geriatric)<BR/>N=82<BR/>Sex 20M, 62F<BR/>Mean age = 80.4+6.6<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=43<BR/>2. Fluoxetine N=39<BR/>20 mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D<BR/>MADRS<BR/>GMS/AGECAT<BR/>MMSE<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jansen-1982">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 21 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Recurring previously treated depression<BR/>Inpatients (Psych)<BR/>N=40<BR/>Sex 7M, 33F<BR/>Mean age = ~70<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=20<BR/>2.= Diclofensine N=20<BR/>50mg/d to 150mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAMD<BR/>Befinlichkeitsskala<BR/>2 test Mosaik<BR/>Critical Flicker Frequency<BR/>5 point global rating scale for depression<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kane-1983">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 28 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis depressed mood and 4 associated symptoms HAM-D &gt;18<BR/>Outpatients (Psych)<BR/>N=44<BR/>Sex 13M, 31F<BR/>Mean age = 63.9+6.98<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=7<BR/>2. Bupropion (LD)N =11<BR/>150mg/d<BR/>3. Bupropion (HD)N=13<BR/>300mg/d<BR/>4. Imipramine N=13<BR/>75-200mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D<BR/>HAMA<BR/>CGI<BR/>Zung SDS<BR/>Zung SAS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Katz-1990-a">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 49 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Major Depressive Disorder DSMIIIR HAM-D &gt;18<BR/>Nursing home or Sheltered housing<BR/>N=30<BR/>Sex 7M, 21F<BR/>Mean age = 84<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=7<BR/>2. Nortriptyline N=18<BR/>start 25mg/d increased to therapeutic plasma levels<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D<BR/>GDS<BR/>CGI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lakshmanan-1986">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 21 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis depressed HAM-D &gt;18 <BR/>MMSE &gt;20<BR/>Inpatients (Rehab Unit)<BR/>N=29<BR/>Sex unknown<BR/>Mean age = 75.6 sd4.1<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N= ?<BR/>2. Doxepin N= ?<BR/>10 - 20mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D<BR/>GDS<BR/>HVID<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Number completing given but not start number</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Meignan_x002d_Debray-1990">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 42 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Major Depressive Disorder DSMIII or <BR/>MADRS &gt;20<BR/>Inpatients (Psych)<BR/>N= 101<BR/>Sex 10M, 91F<BR/>Mean age = ~82.5<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=48<BR/>2. Medifoxamine N=53<BR/>(100mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MADRS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Merideth-1984">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 35 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Primary Depressive Disorder Feighner Criteria<BR/>HAM-D &gt;18<BR/>Inpatients<BR/>N=61<BR/>Sex 16M, 45F<BR/>Mean age = ~68<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=19<BR/>2. Nomifensine N=22<BR/>50 - 200mg/d<BR/>3. Imipramine N=20<BR/>50 - 200mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D<BR/>CGI</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nair-1995">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 49 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Major Depressive Disorder DSMIIIR <BR/>HAM-D &gt;18<BR/>CGI &gt;Moderate<BR/>Unknown recruitment<BR/>N=109<BR/>Sex 32M, 77F<BR/>Mean age = ~69<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=35<BR/>2. Moclobemide N=36<BR/>100 -400mg/d <BR/>3. Nortriptyline N=38<BR/>25 -75mg/d to serum levels 50-170ng/ml</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>GDS<BR/>HAM-D<BR/>CGIS<BR/>MMSE<BR/>CGIE<BR/>CGIT<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Parnetti-1991">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 49 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Prolonged Reactive Depression ICD9<BR/>MMSE &gt;25<BR/>Outpatients (Psych)<BR/>N=130<BR/>Sex 47M, 83F<BR/>Mean age = ~71<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=67<BR/>2. Minaprine N=63<BR/>200mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Evaluation Clinque de la Personalitie<BR/>Symptom Rating Test<BR/>CGI<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tan-1994">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 28 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis depressed BASDEC &gt;6/21<BR/>GDS &gt;15/30<BR/>Inpatients (Psych)<BR/>N=63<BR/>Sex 21M, 42F<BR/>Mean age = 80<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=31<BR/>2. Lofepramine N=32<BR/>70mg/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>MADRS<BR/>GDS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tollefson-1993">
<CHAR_METHODS>
<P>RCT<BR/>Concealment of allocation unclear<BR/>Blindness double<BR/>Duration 42 days<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis Unipolar Major Depression DSMIIIR <BR/>HAM-D &gt;16<BR/>Outpatients<BR/>N=671<BR/>Sex 305M, 366<BR/>Mean age = 67.7 +7.7<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Placebo N=336<BR/>2. Fluoxetine N=335<BR/>20mg/d or every other day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-D<BR/>SF-36<BR/>CGI<BR/>PGI<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Albarede-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study includes patients with dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arcand-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>This is a review of literature not a primary source of data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ather-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>The trial reported does not have a placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Balaceanu-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>The trial reported does not have a placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bella-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Although described as randomised the author describes the randomisation 'Patients were then randomized into two homogenous groups of 30 subjects each with respect to age, sex, education and clinical condition'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bergener-1968-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all the patients in the study were depressed and other psychiatric diagnosis were included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bettini-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients who were included were described as suffering from 'pathological cerebral involution.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bohm-1990-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study included both patients with anxiety or depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonavita-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients included in the study are not all depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Branconnier-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>No interpretable data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Branconnier-1983-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No interpretable data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohn-1990-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study included both patients with bipolar disorder or depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cooper-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were included in the study with co-morbid organicity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dobie-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Inclusion criteria was tinnitus - not all patients were elderly or depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fabre-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Continuation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frederiksen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were included in the study with diagnosis of dementia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gentili-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients with diagnosis of manic depression were included in the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hansgen-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adult population age range 18-70 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hebenstreit-1989-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dose titration study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hubner-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adult population 20-64 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jansen-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No interpretable data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jarvik-1982-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not random allocation 'assignments to one of the trhee groups were made by a non-blind physician who attampted to keep the goups balanced with regard to age, sex and severity of illness'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kivela-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Supportive psychotherapy given to all patients by their GP.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koenig-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study aborted after only three patients randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lapierre-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study 1. Fixed-dose double-blinde controlled study. No ages given so ages checked in paper by Amin et al, 1989 which was cited to have the Canadian arm of the results report - ages given in this 18-65.<BR/>Study 2. Forced upward titration double-blind placebo and amitryptiline controlled study - this study included patients with bipolar affective disorder.<BR/>Study 3. Dose titration double-blinde amitriptyline study in elderly depressives - this study did not have a placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lavie-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uses normal controls and demented subjects in study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McNair-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm, 12 week double-crossover double-blind study of amitriptyline and amoxapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mellow-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised crossover trial: 'Six consecutive patients .... every patients received a 2 week placebo period followed by a 2 week active drug period followed by a crossover back to placebo for an additional 2 weeks'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Middleton-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monti-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a study of elderly patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nyth-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were included in the study with a diagnosis of dementia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petursson-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study included patients with a diagnosis of dementia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raffaele-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all patients in the study were depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reimherr-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subjects were adult not aged</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rothblum-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>All patients received concomitant psychotherapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sakalis-1974-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study included patients who were demented.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schweizer-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No interpretable data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siegfried-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo arm.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sunderland-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study lasted 180 minutes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sunderland-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No interpretable data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taeuber-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reveiw of nomifensine trials - primary sources used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tammaro-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients included in the study were not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tiller-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not all patients were elderly or depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Truffinet-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Sub-sample of elderly from much larger study were reanalysed. The elderly had not been separately randomised in the original study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Von-Knorring-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients with bipolar disorder and dementia were included in the study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wakelin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Meta-analysis paper - primary data in original publications.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wallace-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No interpretable data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weissman-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>All patients received concomitant interpersonal psychotherapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Beutler-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Cohn-1984-b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-De-Leo-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Georgotas-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gerner-1980-a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Halikas-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hammond-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jansen-1982">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kane-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Katz-1990-a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lakshmanan-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Meignan_x002d_Debray-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Merideth-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nair-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Parnetti-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tan-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tollefson-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Data not entered into meta analysis</TITLE>
<TABLE COLS="5" ROWS="24">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Status</P>
</TH>
<TH>
<P>Drug</P>
</TH>
<TH>
<P>Placebo</P>
</TH>
<TH>
<P>Type of Analysis</P>
</TH>
</TR>
<TR>
<TD>
<P>Cohn 1984</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Nomifensine</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Started</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Completed</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Recovered</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>End Point</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Merideth 1984</P>
</TD>
<TD>
<P>Started</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Completed</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Recovered</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>End Point</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Beutler 1987</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Alprozolam</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Started</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Completed</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>HAM-D Mean and (SD)</P>
</TD>
<TD>
<P>22.54 (3.12)</P>
</TD>
<TD>
<P>22.7 (4.19)</P>
</TD>
<TD>
<P>End Point</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Gerner 1980</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Imipramine</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Started</P>
</TD>
<TD>
<P>21</P>
</TD>
<TD>
<P>20</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Completed</P>
</TD>
<TD>
<P>9</P>
</TD>
<TD>
<P>13</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Recovered</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>End Point</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Kane 19</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Buproprion Low dose (High Dose)</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Started</P>
</TD>
<TD>
<P>11 (13)</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Completed</P>
</TD>
<TD>
<P>10 (11)</P>
</TD>
<TD>
<P>5</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Recovered</P>
</TD>
<TD>
<P>5 (6)</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>End Point</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>TCA and related versus Placebo</NAME>
<DICH_OUTCOME CHI2="10.359640714813496" CI_END="0.46858176253491435" CI_START="0.21201033260247903" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3151891104186232" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="167" I2="13.124400278373685" I2_Q="45.245199109796616" ID="CMP-001.01" LOG_CI_END="-0.3292146183950151" LOG_CI_START="-0.6736429726425265" LOG_EFFECT_SIZE="-0.5014287955187707" METHOD="PETO" NO="1" P_CHI2="0.3221623552210584" P_Q="0.12060787181355914" P_Z="1.1515716108245187E-8" Q="7.305295490017336" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="245" TOTAL_2="223" WEIGHT="100.0" Z="5.706744917532823">
<NAME>Recovered</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3651255399240307" CI_START="0.06400805174319943" DF="0.0" EFFECT_SIZE="0.29559943537737077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.13517259188171224" LOG_CI_START="-1.1937653915208883" LOG_EFFECT_SIZE="-0.5292963998195881" NO="2" P_CHI2="1.0" P_Z="0.11846489386686183" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="6.7172013102247" Z="1.5612494995995996">
<NAME>Diclofensine</NAME>
<DICH_DATA CI_END="1.3651255399240307" CI_START="0.06400805174319943" EFFECT_SIZE="0.29559943537737077" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.13517259188171224" LOG_CI_START="-1.1937653915208883" LOG_EFFECT_SIZE="-0.5292963998195881" ORDER="81" O_E="-2.0" SE="0.7806247497997998" STUDY_ID="STD-Jansen-1982" TOTAL_1="20" TOTAL_2="20" VAR="1.641025641025641" WEIGHT="6.7172013102247"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6890834421707991" CI_END="0.6043846011884366" CI_START="0.11993784723522755" DF="2.0" EFFECT_SIZE="0.2692370479125461" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="34" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="-0.21868660936293344" LOG_CI_START="-0.9210437505812145" LOG_EFFECT_SIZE="-0.569865179972074" NO="4" P_CHI2="0.7085450749590773" P_Z="0.0014703300968648418" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="47" WEIGHT="24.048156419674072" Z="3.180476607246689">
<NAME>Imipramine</NAME>
<DICH_DATA CI_END="1.3001380897177528" CI_START="0.11778425356370353" EFFECT_SIZE="0.39132568843246796" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.11398948185874108" LOG_CI_START="-0.9289127659792594" LOG_EFFECT_SIZE="-0.4074616420602591" ORDER="82" O_E="-2.5" SE="0.6126059428294272" STUDY_ID="STD-Cohn-1984-b" TOTAL_1="21" TOTAL_2="21" VAR="2.6646341463414633" WEIGHT="10.907132424748434"/>
<DICH_DATA CI_END="1.2706405972215349" CI_START="0.034705944277123056" EFFECT_SIZE="0.20999709941668468" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.10402272701658194" LOG_CI_START="-1.4595961348442477" LOG_EFFECT_SIZE="-0.6777867039138329" ORDER="83" O_E="-1.8499999999999996" SE="0.9184774594952473" STUDY_ID="STD-Kane-1983" TOTAL_1="13" TOTAL_2="7" VAR="1.1853947368421052" WEIGHT="4.852169814039389"/>
<DICH_DATA CI_END="0.754697441349389" CI_START="0.048022092307808385" EFFECT_SIZE="0.19037371192721741" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="-0.12222712239461642" LOG_CI_START="-1.3185589217896134" LOG_EFFECT_SIZE="-0.720393022092115" ORDER="84" O_E="-3.3589743589743595" SE="0.702731220902536" STUDY_ID="STD-Merideth-1984" TOTAL_1="20" TOTAL_2="19" VAR="2.024983563445102" WEIGHT="8.288854180886249"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4520074620143504" CI_END="0.3984525114491599" CI_START="0.09329350340234632" DF="2.0" EFFECT_SIZE="0.19280308797463708" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="59" I2="0.0" ID="CMP-001.01.06" LOG_CI_END="-0.3996234314687348" LOG_CI_START="-1.0301485977834766" LOG_EFFECT_SIZE="-0.7148860146261056" NO="6" P_CHI2="0.48383876177549756" P_Z="8.814032915980816E-6" STUDIES="3" TAU2="0.0" TOTAL_1="79" TOTAL_2="66" WEIGHT="29.839596233867987" Z="4.444393076038217">
<NAME>Nortriptyline</NAME>
<DICH_DATA CI_END="0.35769965565410067" CI_START="0.0374762736784898" EFFECT_SIZE="0.11578104417388296" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="-0.4464814779320926" LOG_CI_START="-1.4262435981824193" LOG_EFFECT_SIZE="-0.9363625380572559" ORDER="85" O_E="-6.509433962264151" SE="0.5755171193357553" STUDY_ID="STD-Georgotas-1986" TOTAL_1="25" TOTAL_2="28" VAR="3.019141769586768" WEIGHT="12.358236546351124"/>
<DICH_DATA CI_END="1.120281514998092" CI_START="0.043525280893605814" EFFECT_SIZE="0.22081795130877888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.04932717003409047" LOG_CI_START="-1.3612584174501632" LOG_EFFECT_SIZE="-0.6559656237080363" ORDER="86" O_E="-2.1999999999999993" SE="0.8285849565995211" STUDY_ID="STD-Katz-1990-a" TOTAL_1="18" TOTAL_2="12" VAR="1.456551724137931" WEIGHT="5.9620952319028895"/>
<DICH_DATA CI_END="0.9991539475456918" CI_START="0.09656466538865902" EFFECT_SIZE="0.31061707392947263" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="-3.675914350609368E-4" LOG_CI_START="-1.015181760064763" LOG_EFFECT_SIZE="-0.507774675749912" ORDER="87" O_E="-3.29032258064516" SE="0.5961068660642382" STUDY_ID="STD-Nair-1995" TOTAL_1="36" TOTAL_2="26" VAR="2.8141792190511934" WEIGHT="11.519264455613973"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Lofepramine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9132543206110104" CI_END="1.587701257407624" CI_START="0.3490609252201514" DF="1.0" EFFECT_SIZE="0.7444491049654792" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="52" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="0.20076878873037576" LOG_CI_START="-0.45709876450883746" LOG_EFFECT_SIZE="-0.12816498788923078" NO="8" P_CHI2="0.33925255702169155" P_Z="0.44506048040099866" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="68" WEIGHT="27.41074623171514" Z="0.7636757858175259">
<NAME>Trazodone</NAME>
<DICH_DATA CI_END="1.752531745725184" CI_START="0.09245239142120978" EFFECT_SIZE="0.4025242240336361" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.24366589361067942" LOG_CI_START="-1.0340818506745977" LOG_EFFECT_SIZE="-0.39520797853195905" ORDER="88" O_E="-1.615384615384615" SE="0.7505553499465134" STUDY_ID="STD-Gerner-1980-a" TOTAL_1="19" TOTAL_2="20" VAR="1.775147928994083" WEIGHT="7.266203340387297"/>
<DICH_DATA CI_END="2.2483135797495497" CI_START="0.3841136343343896" EFFECT_SIZE="0.929305063066462" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="35" LOG_CI_END="0.3518568836128914" LOG_CI_START="-0.4155402770287881" LOG_EFFECT_SIZE="-0.031841696707948376" ORDER="89" O_E="-0.3608247422680435" SE="0.450772890838132" STUDY_ID="STD-Halikas-1995" TOTAL_1="49" TOTAL_2="48" VAR="4.921351897119779" WEIGHT="20.144542891327845"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6710135860128262" CI_START="0.06788928378235932" DF="0.0" EFFECT_SIZE="0.21343531048690922" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" I2="0.0" ID="CMP-001.01.09" LOG_CI_END="-0.17326868658112848" LOG_CI_START="-1.168198773016726" LOG_EFFECT_SIZE="-0.6707337297989272" NO="9" P_CHI2="1.0" P_Z="0.008226590044514294" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="22" WEIGHT="11.984299804518095" Z="2.642625791590661">
<NAME>Viloxazine</NAME>
<DICH_DATA CI_END="0.6710135860128262" CI_START="0.06788928378235932" EFFECT_SIZE="0.21343531048690922" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.17326868658112848" LOG_CI_START="-1.168198773016726" LOG_EFFECT_SIZE="-0.6707337297989272" ORDER="90" O_E="-4.521739130434783" SE="0.5844268577556269" STUDY_ID="STD-De-Leo-1984" TOTAL_1="24" TOTAL_2="22" VAR="2.9277882797731567" WEIGHT="11.984299804518095"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.418189803407002" CI_START="-13.781810196592996" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.001142507688039016" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="3.2528575203559096">
<NAME>Hamilton Depression Rating Scale</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Diclofensine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Imipramine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nomifensine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.418189803407002" CI_START="-13.781810196592996" DF="0.0" EFFECT_SIZE="-8.6" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.06" NO="6" P_CHI2="1.0" P_Z="0.001142507688039016" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="3.2528575203559096">
<NAME>Nortriptyline</NAME>
<CONT_DATA CI_END="-3.418189803407002" CI_START="-13.781810196592996" EFFECT_SIZE="-8.6" ESTIMABLE="YES" MEAN_1="13.1" MEAN_2="21.7" ORDER="91" SD_1="6.7" SD_2="5.7" SE="2.643829293531134" STUDY_ID="STD-Katz-1990-a" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.07" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Lofepramine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trazodone</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Viloxazine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.775839511287536" CI_END="-0.32449550346075373" CI_START="-5.488983857363699" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.9067396804122265" ESTIMABLE="YES" I2="47.03164702786815" I2_Q="47.03164702786815" ID="CMP-001.03" NO="3" P_CHI2="0.1513865108153536" P_Q="0.1513865108153536" P_Z="0.027365717760696948" Q="3.775839511287536" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="52" UNITS="" WEIGHT="100.0" Z="2.2062611804462575">
<NAME>Other observer rating scales</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Diclofensine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7501004954512638" CI_START="-8.849899504548736" DF="0.0" EFFECT_SIZE="-4.8" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" NO="3" P_CHI2="1.0" P_Z="0.02018033864283174" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="13" WEIGHT="40.65426560807312" Z="2.322977919631252">
<NAME>Doxepin</NAME>
<CONT_DATA CI_END="-0.7501004954512638" CI_START="-8.849899504548736" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="11.5" ORDER="92" SD_1="3.8" SD_2="6.2" SE="2.0663132264132535" STUDY_ID="STD-Lakshmanan-1986" TOTAL_1="11" TOTAL_2="13" WEIGHT="40.65426560807312"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Imipramine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.05" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nomifensine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5171986534500439" CI_START="-12.317198653450042" DF="0.0" EFFECT_SIZE="-5.899999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.06" NO="6" P_CHI2="1.0" P_Z="0.07154551502676526" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="16.192117478385036" Z="1.8019993042555014">
<NAME>Nortriptyline</NAME>
<CONT_DATA CI_END="0.5171986534500439" CI_START="-12.317198653450042" EFFECT_SIZE="-5.899999999999999" ESTIMABLE="YES" MEAN_1="13.3" MEAN_2="19.2" ORDER="93" SD_1="7.2" SD_2="8.0" SE="3.2741411087489802" STUDY_ID="STD-Katz-1990-a" TOTAL_1="12" TOTAL_2="10" WEIGHT="16.192117478385036"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.9308702220872034" CI_START="-3.9308702220872034" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.07" NO="7" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="43.153616913541846" Z="0.0">
<NAME>Lofepramine</NAME>
<CONT_DATA CI_END="3.9308702220872034" CI_START="-3.9308702220872034" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="7.4" ORDER="94" SD_1="8.6" SD_2="6.1" SE="2.005582884733294" STUDY_ID="STD-Tan-1994" TOTAL_1="27" TOTAL_2="29" WEIGHT="43.153616913541846"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.08" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Trazodone</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.09" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Viloxazine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.618173285234711" CI_END="1.3536519250310677" CI_START="0.609688562639533" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9084635911727165" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="71" I2="15.239657912579846" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.13150700521175177" LOG_CI_START="-0.2148919519833754" LOG_EFFECT_SIZE="-0.041692473385811814" METHOD="PETO" NO="4" P_CHI2="0.3027914989113526" P_Q="0.6883062318390851" P_Z="0.6370685952270545" Q="2.2586557062412815" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="280" TOTAL_2="263" WEIGHT="100.00000000000001" Z="0.4718013409985831">
<NAME>Discontinuation rates</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.057289137848248" CI_START="0.048497840799158906" DF="0.0" EFFECT_SIZE="0.49524499339486505" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.7039177840423393" LOG_CI_START="-1.3142775964469093" LOG_EFFECT_SIZE="-0.305179906202285" NO="2" P_CHI2="1.0" P_Z="0.5533491609753078" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="2.945959257981033" Z="0.592748978363819">
<NAME>Diclofensine</NAME>
<DICH_DATA CI_END="5.057289137848246" CI_START="0.04849784079915892" EFFECT_SIZE="0.49524499339486505" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7039177840423391" LOG_CI_START="-1.3142775964469091" LOG_EFFECT_SIZE="-0.305179906202285" ORDER="95" O_E="-0.5" SE="1.1854979567276382" STUDY_ID="STD-Jansen-1982" TOTAL_1="20" TOTAL_2="20" VAR="0.7115384615384616" WEIGHT="2.945959257981033"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.06219866564277" CI_END="1.391677179409943" CI_START="0.20991833644859648" DF="2.0" EFFECT_SIZE="0.5404984351274388" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="0.14353850577719207" LOG_CI_START="-0.677949623968199" LOG_EFFECT_SIZE="-0.2672055590955035" NO="4" P_CHI2="0.5879583505176696" P_Z="0.20229669561518404" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="47" WEIGHT="17.7807701162553" Z="1.2750355198885068">
<NAME>Imipramine</NAME>
<DICH_DATA CI_END="5.516944125155105" CI_START="0.1812597657896138" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7416985855057375" LOG_CI_START="-0.7416985855057375" LOG_EFFECT_SIZE="0.0" ORDER="96" O_E="0.0" SE="0.8713548411865623" STUDY_ID="STD-Cohn-1984-b" TOTAL_1="21" TOTAL_2="21" VAR="1.3170731707317076" WEIGHT="5.453034671332065"/>
<DICH_DATA CI_END="2.591988571006739" CI_START="0.017183188693658837" EFFECT_SIZE="0.21104177005374056" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.41363308224498707" LOG_CI_START="-1.7648962407631847" LOG_EFFECT_SIZE="-0.675631579259099" ORDER="97" O_E="-0.95" SE="1.2796789082290696" STUDY_ID="STD-Kane-1983" TOTAL_1="13" TOTAL_2="7" VAR="0.6106578947368421" WEIGHT="2.5282867697264533"/>
<DICH_DATA CI_END="1.7488817609534677" CI_START="0.1368353925272148" EFFECT_SIZE="0.48919211179633143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.24276044852883125" LOG_CI_START="-0.8638015576504816" LOG_EFFECT_SIZE="-0.31052055456082517" ORDER="98" O_E="-1.6923076923076925" SE="0.65" STUDY_ID="STD-Merideth-1984" TOTAL_1="20" TOTAL_2="19" VAR="2.3668639053254434" WEIGHT="9.799448675196782"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Nomifensine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.235528425142776" CI_END="1.7133231135810383" CI_START="0.4560831575431783" DF="2.0" EFFECT_SIZE="0.8839784021873778" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="28" I2="72.35861871469969" ID="CMP-001.04.06" LOG_CI_END="0.23383927377254018" LOG_CI_START="-0.3409559652971366" LOG_EFFECT_SIZE="-0.05355834576229823" NO="6" P_CHI2="0.02684268206398055" P_Z="0.7149236346544089" STUDIES="3" TAU2="0.0" TOTAL_1="82" TOTAL_2="75" WEIGHT="36.31841001739208" Z="0.3652515596181657">
<NAME>Nortriptyline</NAME>
<DICH_DATA CI_END="0.8736690684629924" CI_START="0.08617800863910532" EFFECT_SIZE="0.2743921655764298" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.0586530398560946" LOG_CI_START="-1.0646035456043472" LOG_EFFECT_SIZE="-0.561628292730221" ORDER="99" O_E="-3.7037037037037033" SE="0.590900306611836" STUDY_ID="STD-Georgotas-1986" TOTAL_1="26" TOTAL_2="28" VAR="2.8639904754509926" WEIGHT="11.85768544075855"/>
<DICH_DATA CI_END="21.09204349907996" CI_START="0.7067823362695598" EFFECT_SIZE="3.8610210801003033" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3241186583255993" LOG_CI_START="-0.15071431281060224" LOG_EFFECT_SIZE="0.5867021727574984" ORDER="100" O_E="1.7999999999999998" SE="0.8663241877863536" STUDY_ID="STD-Katz-1990-a" TOTAL_1="18" TOTAL_2="12" VAR="1.3324137931034483" WEIGHT="5.516548944898537"/>
<DICH_DATA CI_END="2.9918828085225186" CI_START="0.478719187807326" EFFECT_SIZE="1.1967755462535994" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.475944578293771" LOG_CI_START="-0.31991916497295786" LOG_EFFECT_SIZE="0.07801270666040655" ORDER="101" O_E="0.8219178082191796" SE="0.4674943023839426" STUDY_ID="STD-Nair-1995" TOTAL_1="38" TOTAL_2="35" VAR="4.575592669043597" WEIGHT="18.944175631734993"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3861632141933415" CI_START="0.3722908638540996" DF="0.0" EFFECT_SIZE="1.122781202266503" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-001.04.07" LOG_CI_END="0.5297078874159218" LOG_CI_START="-0.4291176213868597" LOG_EFFECT_SIZE="0.050295133014531083" NO="7" P_CHI2="1.0" P_Z="0.8370880816705053" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="31" WEIGHT="13.051907664566958" Z="0.20561958020749388">
<NAME>Lofepramine</NAME>
<DICH_DATA CI_END="3.3861632141933424" CI_START="0.3722908638540995" EFFECT_SIZE="1.122781202266503" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.529707887415922" LOG_CI_START="-0.4291176213868599" LOG_EFFECT_SIZE="0.050295133014531083" ORDER="102" O_E="0.36507936507936556" SE="0.5632188501335694" STUDY_ID="STD-Tan-1994" TOTAL_1="32" TOTAL_2="31" VAR="3.152431342907533" WEIGHT="13.051907664566958"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.06179048820788298" CI_END="2.566556206419857" CI_START="0.5968844742707746" DF="1.0" EFFECT_SIZE="1.237714648840883" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="19" I2="0.0" ID="CMP-001.04.08" LOG_CI_END="0.40935077955361143" LOG_CI_START="-0.2241097175168078" LOG_EFFECT_SIZE="0.09262053101840186" NO="8" P_CHI2="0.803688061614314" P_Z="0.5665453545822758" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="68" WEIGHT="29.90295294380464" Z="0.5731467261639277">
<NAME>Trazodone</NAME>
<DICH_DATA CI_END="3.9355399215429894" CI_START="0.29699259222140295" EFFECT_SIZE="1.0811226586700833" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.5950043221744752" LOG_CI_START="-0.5272543829975679" LOG_EFFECT_SIZE="0.0338749695884537" ORDER="103" O_E="0.17948717948717974" SE="0.6592203186882429" STUDY_ID="STD-Gerner-1980-a" TOTAL_1="19" TOTAL_2="20" VAR="2.3011176857330704" WEIGHT="9.527241767552429"/>
<DICH_DATA CI_END="3.189974893978699" CI_START="0.5449919713148336" EFFECT_SIZE="1.3185259595147447" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.5037872650479586" LOG_CI_START="-0.2636098955937209" LOG_EFFECT_SIZE="0.1200886847271188" ORDER="104" O_E="1.3608247422680417" SE="0.450772890838132" STUDY_ID="STD-Halikas-1995" TOTAL_1="49" TOTAL_2="48" VAR="4.921351897119779" WEIGHT="20.37571117625221"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Viloxazine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="105" O_E="0.0" SE="0.0" STUDY_ID="STD-De-Leo-1984" TOTAL_1="24" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>SSRI and related versus Placebo</NAME>
<DICH_OUTCOME CHI2="0.16951667163673467" CI_END="0.7161946104866173" CI_START="0.35891013444027103" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5070004969772213" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="310" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.14496895146811076" LOG_CI_START="-0.4450142784476274" LOG_EFFECT_SIZE="-0.294991614957869" METHOD="PETO" NO="1" P_CHI2="0.6805419823709287" P_Q="1.0" P_Z="1.1624919747260179E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="365" TOTAL_2="372" WEIGHT="99.99999999999999" Z="3.8539039876345145">
<NAME>Recovered</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.16951667163673467" CI_END="0.7161946104866173" CI_START="0.35891013444027103" DF="1.0" EFFECT_SIZE="0.5070004969772213" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="310" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.14496895146811076" LOG_CI_START="-0.4450142784476274" LOG_EFFECT_SIZE="-0.294991614957869" NO="1" P_CHI2="0.6805419823709287" P_Z="1.1624919747260179E-4" STUDIES="2" TAU2="0.0" TOTAL_1="365" TOTAL_2="372" WEIGHT="99.99999999999999" Z="3.8539039876345145">
<NAME>Fluoxetine</NAME>
<DICH_DATA CI_END="1.1074367161053393" CI_START="0.15844764543682094" EFFECT_SIZE="0.4188922774857232" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="35" LOG_CI_END="0.04431891807207822" LOG_CI_START="-0.8001142101271597" LOG_EFFECT_SIZE="-0.3778976460275407" ORDER="106" O_E="-3.5365853658536572" SE="0.49602419951563126" STUDY_ID="STD-Hammond-1993" TOTAL_1="39" TOTAL_2="43" VAR="4.064379668186926" WEIGHT="12.625343671231779"/>
<DICH_DATA CI_END="0.7541956048961695" CI_START="0.36015716376749096" EFFECT_SIZE="0.5211803430534497" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="275" LOG_CI_END="-0.122516002790784" LOG_CI_START="-0.4435079423929169" LOG_EFFECT_SIZE="-0.2830119725918505" ORDER="107" O_E="-18.329770992366406" SE="0.18855225425801994" STUDY_ID="STD-Tollefson-1993" TOTAL_1="326" TOTAL_2="329" VAR="28.127850294218437" WEIGHT="87.37465632876821"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.4154950498206683E-31" CI_END="-0.5432643006906561" CI_START="-2.856735699309343" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6999999999999995" ESTIMABLE="YES" I2="99.99999999999999" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.00397086775542205" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="329" UNITS="" WEIGHT="100.0" Z="2.8804667960948254">
<NAME>Hamilton Depression Rating Scale</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.4154950498206683E-31" CI_END="-0.5432643006906561" CI_START="-2.856735699309343" DF="0.0" EFFECT_SIZE="-1.6999999999999995" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-002.02.01" NO="1" P_CHI2="0.0" P_Z="0.00397086775542205" STUDIES="1" TAU2="0.0" TOTAL_1="326" TOTAL_2="329" WEIGHT="100.0" Z="2.8804667960948254">
<NAME>Fluoxetine</NAME>
<CONT_DATA CI_END="-0.5432643006906559" CI_START="-2.8567356993093425" EFFECT_SIZE="-1.6999999999999993" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="15.7" ORDER="108" SD_1="7.7" SD_2="7.4" SE="0.590182119892777" STUDY_ID="STD-Tollefson-1993" TOTAL_1="326" TOTAL_2="329" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.38048223598853625" CI_START="-1.9804822359885377" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.18409674633388018" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="326" TOTAL_2="329" UNITS="" WEIGHT="100.0" Z="1.328246321571306">
<NAME>Other observer rating scales</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.38048223598853625" CI_START="-1.9804822359885377" DF="0.0" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="1.0" P_Z="0.18409674633388018" STUDIES="1" TAU2="0.0" TOTAL_1="326" TOTAL_2="329" WEIGHT="100.0" Z="1.328246321571306">
<NAME>Fluoxetine</NAME>
<CONT_DATA CI_END="0.38048223598853625" CI_START="-1.9804822359885377" EFFECT_SIZE="-0.8000000000000007" ESTIMABLE="YES" MEAN_1="15.8" MEAN_2="16.6" ORDER="109" SD_1="8.0" SD_2="7.4" SE="0.6022979224618565" STUDY_ID="STD-Tollefson-1993" TOTAL_1="326" TOTAL_2="329" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.4122738148828845" CI_END="1.5178269607967882" CI_START="0.7408691763437438" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0604297290616878" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="80" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.18122226282779821" LOG_CI_START="-0.13025847354299389" LOG_EFFECT_SIZE="0.025481894642402185" METHOD="PETO" NO="4" P_CHI2="0.5208176727370469" P_Q="1.0" P_Z="0.7484491366944643" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="365" TOTAL_2="372" WEIGHT="99.99999999999999" Z="0.3206849729384143">
<NAME>Discontinuation rates</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4122738148828845" CI_END="1.5178269607967882" CI_START="0.7408691763437438" DF="1.0" EFFECT_SIZE="1.0604297290616878" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="80" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.18122226282779821" LOG_CI_START="-0.13025847354299389" LOG_EFFECT_SIZE="0.025481894642402185" NO="1" P_CHI2="0.5208176727370469" P_Z="0.7484491366944643" STUDIES="2" TAU2="0.0" TOTAL_1="365" TOTAL_2="372" WEIGHT="99.99999999999999" Z="0.3206849729384143">
<NAME>Fluoxetine</NAME>
<DICH_DATA CI_END="1.9420065555457495" CI_START="0.3465299091284851" EFFECT_SIZE="0.8203434373603478" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.28825069160315986" LOG_CI_START="-0.4602592753122473" LOG_EFFECT_SIZE="-0.08600429185454372" ORDER="110" O_E="-1.0243902439024382" SE="0.43967845975020287" STUDY_ID="STD-Hammond-1993" TOTAL_1="39" TOTAL_2="43" VAR="5.172846850419724" WEIGHT="17.316782818291873"/>
<DICH_DATA CI_END="1.6599899499192328" CI_START="0.7543217185364889" EFFECT_SIZE="1.119002444937622" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="58" LOG_CI_END="0.22010545869798734" LOG_CI_START="-0.12244338783653688" LOG_EFFECT_SIZE="0.048831035430725186" ORDER="111" O_E="2.77709923664122" SE="0.2012148880985169" STUDY_ID="STD-Tollefson-1993" TOTAL_1="326" TOTAL_2="329" VAR="24.699023142403647" WEIGHT="82.68321718170812"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>MAOI and related versus Placebo</NAME>
<DICH_OUTCOME CHI2="0.9146546564048883" CI_END="0.39205491800844955" CI_START="0.0746420281202794" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.17106657830996833" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="57" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.4066530939043251" LOG_CI_START="-1.127016568759418" LOG_EFFECT_SIZE="-0.7668348313318716" METHOD="PETO" NO="1" P_CHI2="0.33888254517988947" P_Q="0.33888254517988947" P_Z="3.0087061277948006E-5" Q="0.9146546564048883" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="63" WEIGHT="100.0" Z="4.172806378901012">
<NAME>Recovered</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8121345762791262" CI_START="0.07963636100877554" DF="0.0" EFFECT_SIZE="0.25431366912589154" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="32" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="-0.09037199921606344" LOG_CI_START="-1.0988885933196162" LOG_EFFECT_SIZE="-0.5946302962678398" NO="1" P_CHI2="1.0" P_Z="0.020820475908557498" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="51.01962612187971" Z="2.3112241714521193">
<NAME>Moclobemine</NAME>
<DICH_DATA CI_END="0.812134576279126" CI_START="0.07963636100877558" EFFECT_SIZE="0.25431366912589154" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="32" LOG_CI_END="-0.09037199921606355" LOG_CI_START="-1.098888593319616" LOG_EFFECT_SIZE="-0.5946302962678398" ORDER="112" O_E="-3.901408450704224" SE="0.5924076396140813" STUDY_ID="STD-Nair-1995" TOTAL_1="36" TOTAL_2="35" VAR="2.849434635984924" WEIGHT="51.01962612187971"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.37020260852177245" CI_START="0.0346053018520686" DF="0.0" EFFECT_SIZE="0.11318556893137535" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-0.43156052544637646" LOG_CI_START="-1.4608573581811792" LOG_EFFECT_SIZE="-0.9462089418137779" NO="2" P_CHI2="1.0" P_Z="3.1396103050240304E-4" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="28" WEIGHT="48.98037387812029" Z="3.6034997657135115">
<NAME>Phenelzine</NAME>
<DICH_DATA CI_END="0.37020260852177245" CI_START="0.0346053018520686" EFFECT_SIZE="0.11318556893137535" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="25" LOG_CI_END="-0.43156052544637646" LOG_CI_START="-1.4608573581811792" LOG_EFFECT_SIZE="-0.9462089418137779" ORDER="113" O_E="-5.960000000000001" SE="0.6046140546499179" STUDY_ID="STD-Georgotas-1986" TOTAL_1="22" TOTAL_2="28" VAR="2.735542857142857" WEIGHT="48.98037387812029"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Hamilton Depression Rating Scale</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Moclobemine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Phenelzine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Other observer rating scales</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Moclobemine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-003.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Phenelzine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.598249534869892" CI_END="1.7487616401116477" CI_START="0.40179003648194533" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8382332629875084" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" I2="86.83907398130583" I2_Q="86.83907398130583" ID="CMP-003.04" LOG_CI_END="0.2427306182615326" LOG_CI_START="-0.39600083701176764" LOG_EFFECT_SIZE="-0.0766351093751175" METHOD="PETO" NO="4" P_CHI2="0.005842552687360891" P_Q="0.005842552687360891" P_Z="0.6381309632368252" Q="7.598249534869892" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="57" WEIGHT="100.0" Z="0.470313628948334">
<NAME>Discontinuation rates</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.638900022924587" CI_START="0.7308275160650848" DF="0.0" EFFECT_SIZE="1.8412592921770257" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.6664150127515573" LOG_CI_START="-0.13618510958131744" LOG_EFFECT_SIZE="0.26511495158511994" NO="1" P_CHI2="1.0" P_Z="0.1953785377012745" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="63.3341819107539" Z="1.2948309934455928">
<NAME>Moclobemine</NAME>
<DICH_DATA CI_END="4.638900022924587" CI_START="0.7308275160650848" EFFECT_SIZE="1.8412592921770257" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.6664150127515573" LOG_CI_START="-0.13618510958131744" LOG_EFFECT_SIZE="0.26511495158511994" ORDER="114" O_E="2.746478873239436" SE="0.47145128479301085" STUDY_ID="STD-Nair-1995" TOTAL_1="36" TOTAL_2="35" VAR="4.499107319976195" WEIGHT="63.3341819107539"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7252187166393511" CI_START="0.06391849135210581" DF="0.0" EFFECT_SIZE="0.21530184919758036" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="-0.13953099604330035" LOG_CI_START="-1.194373484088116" LOG_EFFECT_SIZE="-0.6669522400657082" NO="2" P_CHI2="1.0" P_Z="0.013194395334006794" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="22" WEIGHT="36.6658180892461" Z="2.47847879612821">
<NAME>Phenelzine</NAME>
<DICH_DATA CI_END="0.7252187166393511" CI_START="0.06391849135210581" EFFECT_SIZE="0.21530184919758036" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="12" LOG_CI_END="-0.13953099604330035" LOG_CI_START="-1.194373484088116" LOG_EFFECT_SIZE="-0.6669522400657082" ORDER="115" O_E="-4.0" SE="0.6196196990320526" STUDY_ID="STD-Georgotas-1986" TOTAL_1="22" TOTAL_2="22" VAR="2.604651162790698" WEIGHT="36.6658180892461"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Atypical Antidepressants</NAME>
<DICH_OUTCOME CHI2="0.02752742269597047" CI_END="0.9285666693476474" CI_START="0.28984309155616494" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5187857304897016" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.032186909274395346" LOG_CI_START="-0.5378370466293905" LOG_EFFECT_SIZE="-0.285011977951893" METHOD="PETO" NO="1" P_CHI2="0.8682247333622195" P_Q="0.8682247333622195" P_Z="0.02714092046148028" Q="0.02752742269597047" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="96" WEIGHT="100.0" Z="2.209485059651258">
<NAME>Recovered</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Minaprine</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2589470679940882" CI_START="0.2366256268099376" DF="0.0" EFFECT_SIZE="0.545801373289436" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.10000747072633774" LOG_CI_START="-0.625938222601368" LOG_EFFECT_SIZE="-0.26296537593751507" NO="2" P_CHI2="1.0" P_Z="0.15562274139920534" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="48" WEIGHT="48.516782599597825" Z="1.4199482709401592">
<NAME>Mirtazepine</NAME>
<DICH_DATA CI_END="1.2589470679940882" CI_START="0.23662562680993765" EFFECT_SIZE="0.545801373289436" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="35" LOG_CI_END="0.10000747072633774" LOG_CI_START="-0.6259382226013679" LOG_EFFECT_SIZE="-0.26296537593751507" ORDER="116" O_E="-3.3298969072164937" SE="0.42642409374983126" STUDY_ID="STD-Halikas-1995" TOTAL_1="49" TOTAL_2="48" VAR="5.499415453289403" WEIGHT="48.516782599597825"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1131976865271505" CI_START="0.21971068152891587" DF="0.0" EFFECT_SIZE="0.49455173883355485" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.04657229510223476" LOG_CI_START="-0.6581488287585942" LOG_EFFECT_SIZE="-0.3057882668281797" NO="3" P_CHI2="1.0" P_Z="0.08895968255442202" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="48" WEIGHT="51.48321740040217" Z="1.7009110968454952">
<NAME>Medifoxamine</NAME>
<DICH_DATA CI_END="1.1131976865271505" CI_START="0.21971068152891587" EFFECT_SIZE="0.49455173883355485" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.04657229510223476" LOG_CI_START="-0.6581488287585942" LOG_EFFECT_SIZE="-0.3057882668281797" ORDER="117" O_E="-4.10891089108911" SE="0.4139566765816747" STUDY_ID="STD-Meignan_x002d_Debray-1990" TOTAL_1="53" TOTAL_2="48" VAR="5.8356631702774235" WEIGHT="51.48321740040217"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Hamilton Depression Rating Scale</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Minaprine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mirtazepine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.02.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Medifoxamine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7475543378399827" CI_START="-7.947554337839971" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.5999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.10459974800512839" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="64" UNITS="" WEIGHT="100.0" Z="1.6229516174028538">
<NAME>Other observer rating scales</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7475543378399827" CI_START="-7.947554337839971" DF="0.0" EFFECT_SIZE="-3.5999999999999943" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" NO="1" P_CHI2="1.0" P_Z="0.10459974800512839" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="64" WEIGHT="100.0" Z="1.6229516174028538">
<NAME>Minaprine</NAME>
<CONT_DATA CI_END="0.7475543378399827" CI_START="-7.947554337839971" EFFECT_SIZE="-3.5999999999999943" ESTIMABLE="YES" MEAN_1="72.0" MEAN_2="75.6" ORDER="118" SD_1="11.9" SD_2="12.7" SE="2.2181807278771095" STUDY_ID="STD-Parnetti-1991" TOTAL_1="59" TOTAL_2="64" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.03.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mirtazepine</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.03.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Medifoxamine</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.8224762220792408" CI_END="1.6001957916036007" CI_START="0.4081840928099365" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8081920981511722" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.2041731239127041" LOG_CI_START="-0.38914392401847314" LOG_EFFECT_SIZE="-0.09248540005288453" METHOD="PETO" NO="4" P_CHI2="0.6628293615661317" P_Q="0.6628293615661317" P_Z="0.5411779483165979" Q="0.8224762220792408" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="165" TOTAL_2="163" WEIGHT="100.0" Z="0.6110326808625898">
<NAME>Discontinuation rates</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.570273549720772" CI_START="0.315536343947777" DF="0.0" EFFECT_SIZE="1.439847246972982" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.8175834515477737" LOG_CI_START="-0.5009506108511488" LOG_EFFECT_SIZE="0.15831642034831245" NO="1" P_CHI2="1.0" P_Z="0.6378793718315894" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="67" WEIGHT="20.248410983601772" Z="0.4706658567158305">
<NAME>Minaprine</NAME>
<DICH_DATA CI_END="6.570273549720772" CI_START="0.315536343947777" EFFECT_SIZE="1.439847246972982" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8175834515477737" LOG_CI_START="-0.5009506108511488" LOG_EFFECT_SIZE="0.15831642034831245" ORDER="119" O_E="0.6076923076923078" SE="0.7745134351019995" STUDY_ID="STD-Parnetti-1991" TOTAL_1="63" TOTAL_2="67" VAR="1.6670249071143524" WEIGHT="20.248410983601772"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9866024816608079" CI_START="0.29977621897224443" DF="0.0" EFFECT_SIZE="0.7717099069943021" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" ID="CMP-004.04.02" LOG_CI_END="0.2981109736560592" LOG_CI_START="-0.5232028223842453" LOG_EFFECT_SIZE="-0.11254592436409315" NO="2" P_CHI2="1.0" P_Z="0.5911613073896985" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="48" WEIGHT="52.1861692575366" Z="0.5371539098061532">
<NAME>Mirtazepine</NAME>
<DICH_DATA CI_END="1.9866024816608079" CI_START="0.29977621897224443" EFFECT_SIZE="0.7717099069943021" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.2981109736560592" LOG_CI_START="-0.5232028223842453" LOG_EFFECT_SIZE="-0.11254592436409315" ORDER="120" O_E="-1.1134020618556697" SE="0.482443789362934" STUDY_ID="STD-Halikas-1995" TOTAL_1="49" TOTAL_2="48" VAR="4.296418322882347" WEIGHT="52.1861692575366"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1198153293438593" CI_START="0.1571195301820914" DF="0.0" EFFECT_SIZE="0.5771173092355683" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-004.04.03" LOG_CI_END="0.3262980284097608" LOG_CI_START="-0.803769828180027" LOG_EFFECT_SIZE="-0.23873589988513302" NO="3" P_CHI2="1.0" P_Z="0.4076046877405066" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="48" WEIGHT="27.56541975886163" Z="0.8281162283540158">
<NAME>Medifoxamine</NAME>
<DICH_DATA CI_END="2.1198153293438593" CI_START="0.1571195301820914" EFFECT_SIZE="0.5771173092355683" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3262980284097608" LOG_CI_START="-0.803769828180027" LOG_EFFECT_SIZE="-0.23873589988513302" ORDER="121" O_E="-1.2475247524752477" SE="0.6638074528869491" STUDY_ID="STD-Meignan_x002d_Debray-1990" TOTAL_1="53" TOTAL_2="48" VAR="2.269424566218998" WEIGHT="27.56541975886163"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Length of Study and recovery</NAME>
<DICH_OUTCOME CHI2="1.0025058635080508" CI_END="0.6297150351180675" CI_START="0.18788922841505806" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.34397190593084037" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-0.20085593733020735" LOG_CI_START="-0.7260981170468601" LOG_EFFECT_SIZE="-0.46347702718853373" METHOD="PETO" NO="2" P_CHI2="0.8006456267310142" P_Q="1.0" P_Z="5.422467559569061E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="143" TOTAL_2="70" WEIGHT="99.99999999999999" Z="3.458969275625435">
<NAME>28 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0928344929332834" CI_START="0.13235776171985958" EFFECT_SIZE="0.38032239930736017" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.03855439411031626" LOG_CI_START="-0.878250585731988" LOG_EFFECT_SIZE="-0.41984809581083576" ORDER="122" O_E="-3.333333333333332" SE="0.5385357834172118" STUDY_ID="STD-Cohn-1984-b" TOTAL_1="42" TOTAL_2="21" VAR="3.448028673835126" WEIGHT="32.82201674452554"/>
<DICH_DATA CI_END="0.6710135860128262" CI_START="0.06788928378235932" EFFECT_SIZE="0.21343531048690922" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.17326868658112848" LOG_CI_START="-1.168198773016726" LOG_EFFECT_SIZE="-0.6707337297989272" ORDER="123" O_E="-4.521739130434783" SE="0.5844268577556269" STUDY_ID="STD-De-Leo-1984" TOTAL_1="24" TOTAL_2="22" VAR="2.9277882797731567" WEIGHT="27.869813459600945"/>
<DICH_DATA CI_END="1.3821789965850764" CI_START="0.12448072196308026" EFFECT_SIZE="0.41479469545440933" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="17" LOG_CI_END="0.14056428919979425" LOG_CI_START="-0.9048979015266819" LOG_EFFECT_SIZE="-0.3821668061634438" ORDER="124" O_E="-2.333333333333332" SE="0.6141096659540394" STUDY_ID="STD-Gerner-1980-a" TOTAL_1="40" TOTAL_2="20" VAR="2.6516007532956682" WEIGHT="25.2407658279899"/>
<DICH_DATA CI_END="2.509836288379832" CI_START="0.09982601600588706" EFFECT_SIZE="0.5005466586602704" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.39964539424118284" LOG_CI_START="-1.000756260963278" LOG_EFFECT_SIZE="-0.3005554333610476" ORDER="125" O_E="-1.0227272727272734" SE="0.8226028643670931" STUDY_ID="STD-Kane-1983" TOTAL_1="37" TOTAL_2="7" VAR="1.4778132807995388" WEIGHT="14.067403967883605"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04412707293165974" CI_END="0.7092970105139789" CI_START="0.38588037507543327" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5231670827345866" ESTIMABLE="YES" EVENTS_1="324" EVENTS_2="345" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-0.1491718705758575" LOG_CI_START="-0.41354730801365835" LOG_EFFECT_SIZE="-0.28135958929475785" METHOD="PETO" NO="4" P_CHI2="0.9781780927996425" P_Q="1.0" P_Z="3.0226369205239117E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="477" TOTAL_2="425" WEIGHT="100.0" Z="4.171754131678339">
<NAME>42 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1340236145833107" CI_START="0.27105512104254" EFFECT_SIZE="0.5544212370715772" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="35" LOG_CI_END="0.054622098275091326" LOG_CI_START="-0.5669423831832128" LOG_EFFECT_SIZE="-0.2561601424540607" ORDER="126" O_E="-4.4246575342465775" SE="0.36511005320241297" STUDY_ID="STD-Halikas-1995" TOTAL_1="98" TOTAL_2="48" VAR="7.501574339495669" WEIGHT="18.091302193681955"/>
<DICH_DATA CI_END="1.1131976865271505" CI_START="0.21971068152891587" EFFECT_SIZE="0.49455173883355485" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.04657229510223476" LOG_CI_START="-0.6581488287585942" LOG_EFFECT_SIZE="-0.3057882668281797" ORDER="127" O_E="-4.10891089108911" SE="0.4139566765816747" STUDY_ID="STD-Meignan_x002d_Debray-1990" TOTAL_1="53" TOTAL_2="48" VAR="5.8356631702774235" WEIGHT="14.07367855547063"/>
<DICH_DATA CI_END="0.7541956048961695" CI_START="0.36015716376749096" EFFECT_SIZE="0.5211803430534497" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="275" LOG_CI_END="-0.122516002790784" LOG_CI_START="-0.4435079423929169" LOG_EFFECT_SIZE="-0.2830119725918505" ORDER="128" O_E="-18.329770992366406" SE="0.18855225425801994" STUDY_ID="STD-Tollefson-1993" TOTAL_1="326" TOTAL_2="329" VAR="28.127850294218437" WEIGHT="67.83501925084741"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1792292863766582" CI_END="0.4197181331331432" CI_START="0.11574126284155334" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.22040577752483986" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="59" I2="8.224434551109471" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="-0.3770422675062931" LOG_CI_START="-0.9365117834021754" LOG_EFFECT_SIZE="-0.6567770254542343" METHOD="PETO" NO="5" P_CHI2="0.3363463244456648" P_Q="1.0" P_Z="4.190285865524354E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="66" WEIGHT="100.0" Z="4.601713870691771">
<NAME>49 days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3519531201237626" CI_START="0.053295613883018435" EFFECT_SIZE="0.1369582330312408" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="-0.4535151803498464" LOG_CI_START="-1.273308531025645" LOG_EFFECT_SIZE="-0.8634118556877457" ORDER="129" O_E="-8.573333333333334" SE="0.4815506722294972" STUDY_ID="STD-Georgotas-1986" TOTAL_1="47" TOTAL_2="28" VAR="4.31236996996997" WEIGHT="46.574057270398825"/>
<DICH_DATA CI_END="1.120281514998092" CI_START="0.043525280893605814" EFFECT_SIZE="0.22081795130877888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.04932717003409047" LOG_CI_START="-1.3612584174501632" LOG_EFFECT_SIZE="-0.6559656237080363" ORDER="130" O_E="-2.1999999999999993" SE="0.8285849565995211" STUDY_ID="STD-Katz-1990-a" TOTAL_1="18" TOTAL_2="12" VAR="1.456551724137931" WEIGHT="15.730914529527382"/>
<DICH_DATA CI_END="1.1319142541948408" CI_START="0.13885775447902252" EFFECT_SIZE="0.39645311399999505" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="23" LOG_CI_END="0.05381352902498219" LOG_CI_START="-0.857429862162101" LOG_EFFECT_SIZE="-0.40180816656855944" ORDER="131" O_E="-3.2291666666666643" SE="0.5352688787108271" STUDY_ID="STD-Nair-1995" TOTAL_1="70" TOTAL_2="26" VAR="3.490245796783626" WEIGHT="37.69502820007379"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Recruitment source and recovery</NAME>
<DICH_OUTCOME CHI2="2.740453563202532" CI_END="0.5777136982499854" CI_START="0.20622934851983893" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.34516882770766144" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="93" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-0.2382873347195356" LOG_CI_START="-0.6856495301619112" LOG_EFFECT_SIZE="-0.4619684324407235" METHOD="PETO" NO="1" P_CHI2="0.433396429921899" P_Q="1.0" P_Z="5.167647815962974E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="153" TOTAL_2="128" WEIGHT="99.99999999999997" Z="4.047912402087951">
<NAME>Institutionalised patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1074367161053393" CI_START="0.15844764543682094" EFFECT_SIZE="0.4188922774857232" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="35" LOG_CI_END="0.04431891807207822" LOG_CI_START="-0.8001142101271597" LOG_EFFECT_SIZE="-0.3778976460275407" ORDER="132" O_E="-3.5365853658536572" SE="0.49602419951563126" STUDY_ID="STD-Hammond-1993" TOTAL_1="39" TOTAL_2="43" VAR="4.064379668186926" WEIGHT="28.066485683133283"/>
<DICH_DATA CI_END="0.854829144596366" CI_START="0.03323842825887939" EFFECT_SIZE="0.16856208706665193" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.06812067939331376" LOG_CI_START="-1.478359520827589" LOG_EFFECT_SIZE="-0.7732401001104514" ORDER="133" O_E="-2.5945945945945947" SE="0.8283812762533432" STUDY_ID="STD-Jansen-1982" TOTAL_1="19" TOTAL_2="18" VAR="1.4572680788897006" WEIGHT="10.06313312527964"/>
<DICH_DATA CI_END="1.1131976865271505" CI_START="0.21971068152891587" EFFECT_SIZE="0.49455173883355485" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.04657229510223476" LOG_CI_START="-0.6581488287585942" LOG_EFFECT_SIZE="-0.3057882668281797" ORDER="134" O_E="-4.10891089108911" SE="0.4139566765816747" STUDY_ID="STD-Meignan_x002d_Debray-1990" TOTAL_1="53" TOTAL_2="48" VAR="5.8356631702774235" WEIGHT="40.29804550548862"/>
<DICH_DATA CI_END="0.580359956247213" CI_START="0.06316990929853392" EFFECT_SIZE="0.19147137069712944" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="-0.23630256070849534" LOG_CI_START="-1.1994897466797099" LOG_EFFECT_SIZE="-0.7178961536941026" ORDER="135" O_E="-5.16393442622951" SE="0.565780920892957" STUDY_ID="STD-Merideth-1984" TOTAL_1="42" TOTAL_2="19" VAR="3.123945176027949" WEIGHT="21.57233568609843"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.51661365163657" CI_END="0.6248748661398026" CI_START="0.3513145542756126" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4685377627000174" ESTIMABLE="YES" EVENTS_1="384" EVENTS_2="370" I2="42.9474144553528" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-0.20420694327356229" LOG_CI_START="-0.45430385786338356" LOG_EFFECT_SIZE="-0.3292554005684729" METHOD="PETO" NO="2" P_CHI2="0.10451521081139681" P_Q="1.0" P_Z="2.461211655015639E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="602" TOTAL_2="468" WEIGHT="100.0" Z="5.160629253566811">
<NAME>Community dwelling patients</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.536502943944559" CI_START="0.0032008098195145454" EFFECT_SIZE="0.16529888822158653" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9312799944371751" LOG_CI_START="-2.4947401292888816" LOG_EFFECT_SIZE="-0.7817300674258533" ORDER="136" O_E="-0.4444444444444444" SE="2.0124611797498106" STUDY_ID="STD-Beutler-1987" TOTAL_1="12" TOTAL_2="15" VAR="0.24691358024691357" WEIGHT="0.5328891142888731"/>
<DICH_DATA CI_END="1.0928344929332834" CI_START="0.13235776171985958" EFFECT_SIZE="0.38032239930736017" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.03855439411031626" LOG_CI_START="-0.878250585731988" LOG_EFFECT_SIZE="-0.41984809581083576" ORDER="137" O_E="-3.333333333333332" SE="0.5385357834172118" STUDY_ID="STD-Cohn-1984-b" TOTAL_1="42" TOTAL_2="21" VAR="3.448028673835126" WEIGHT="7.4415386314726835"/>
<DICH_DATA CI_END="0.3519531201237626" CI_START="0.053295613883018435" EFFECT_SIZE="0.1369582330312408" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="-0.4535151803498464" LOG_CI_START="-1.273308531025645" LOG_EFFECT_SIZE="-0.8634118556877457" ORDER="138" O_E="-8.573333333333334" SE="0.4815506722294972" STUDY_ID="STD-Georgotas-1986" TOTAL_1="47" TOTAL_2="28" VAR="4.31236996996997" WEIGHT="9.306960805822087"/>
<DICH_DATA CI_END="13.378728081447605" CI_START="0.38489792869591927" EFFECT_SIZE="2.269238799054677" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="17" LOG_CI_END="1.1264148269246528" LOG_CI_START="-0.41465442602765656" LOG_EFFECT_SIZE="0.3558802004484981" ORDER="139" O_E="1.0" SE="0.905231707600018" STUDY_ID="STD-Gerner-1980-a" TOTAL_1="40" TOTAL_2="20" VAR="1.2203389830508473" WEIGHT="2.633736707231108"/>
<DICH_DATA CI_END="1.1340236145833107" CI_START="0.27105512104254" EFFECT_SIZE="0.5544212370715772" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="35" LOG_CI_END="0.054622098275091326" LOG_CI_START="-0.5669423831832128" LOG_EFFECT_SIZE="-0.2561601424540607" ORDER="140" O_E="-4.4246575342465775" SE="0.36511005320241297" STUDY_ID="STD-Halikas-1995" TOTAL_1="98" TOTAL_2="48" VAR="7.501574339495669" WEIGHT="16.18990458746124"/>
<DICH_DATA CI_END="2.509836288379832" CI_START="0.09982601600588706" EFFECT_SIZE="0.5005466586602704" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.39964539424118284" LOG_CI_START="-1.000756260963278" LOG_EFFECT_SIZE="-0.3005554333610476" ORDER="141" O_E="-1.0227272727272734" SE="0.8226028643670931" STUDY_ID="STD-Kane-1983" TOTAL_1="37" TOTAL_2="7" VAR="1.4778132807995388" WEIGHT="3.1894179716728797"/>
<DICH_DATA CI_END="0.7541956048961695" CI_START="0.36015716376749096" EFFECT_SIZE="0.5211803430534497" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="275" LOG_CI_END="-0.122516002790784" LOG_CI_START="-0.4435079423929169" LOG_EFFECT_SIZE="-0.2830119725918505" ORDER="142" O_E="-18.329770992366406" SE="0.18855225425801994" STUDY_ID="STD-Tollefson-1993" TOTAL_1="326" TOTAL_2="329" VAR="28.127850294218437" WEIGHT="60.70555218205113"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Types of depression and recovery</NAME>
<DICH_OUTCOME CHI2="7.57973048475137" CI_END="0.5834577503725501" CI_START="0.33529849258755706" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.44230363347868085" ESTIMABLE="YES" EVENTS_1="359" EVENTS_2="428" I2="7.648431377839241" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-0.23399058682407517" LOG_CI_START="-0.4745683990387538" LOG_EFFECT_SIZE="-0.3542794929314144" METHOD="PETO" NO="1" P_CHI2="0.3711060183151541" P_Q="1.0" P_Z="7.807567117172786E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="562" TOTAL_2="538" WEIGHT="100.0" Z="5.77256098735375">
<NAME>Major depressive disorder</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.536502943944559" CI_START="0.0032008098195145454" EFFECT_SIZE="0.16529888822158653" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9312799944371751" LOG_CI_START="-2.4947401292888816" LOG_EFFECT_SIZE="-0.7817300674258533" ORDER="143" O_E="-0.4444444444444444" SE="2.0124611797498106" STUDY_ID="STD-Beutler-1987" TOTAL_1="12" TOTAL_2="15" VAR="0.24691358024691357" WEIGHT="0.4930958223826503"/>
<DICH_DATA CI_END="1.0928344929332834" CI_START="0.13235776171985958" EFFECT_SIZE="0.38032239930736017" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.03855439411031626" LOG_CI_START="-0.878250585731988" LOG_EFFECT_SIZE="-0.41984809581083576" ORDER="144" O_E="-3.333333333333332" SE="0.5385357834172118" STUDY_ID="STD-Cohn-1984-b" TOTAL_1="42" TOTAL_2="21" VAR="3.448028673835126" WEIGHT="6.885844564820947"/>
<DICH_DATA CI_END="0.35769965565410067" CI_START="0.0374762736784898" EFFECT_SIZE="0.11578104417388296" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="-0.4464814779320926" LOG_CI_START="-1.4262435981824193" LOG_EFFECT_SIZE="-0.9363625380572559" ORDER="145" O_E="-6.509433962264151" SE="0.5755171193357553" STUDY_ID="STD-Georgotas-1986" TOTAL_1="25" TOTAL_2="28" VAR="3.019141769586768" WEIGHT="6.029341084745"/>
<DICH_DATA CI_END="1.224589309947663" CI_START="0.23308854552762814" EFFECT_SIZE="0.5342637374222422" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="37" LOG_CI_END="0.08799046394259748" LOG_CI_START="-0.6324790681198087" LOG_EFFECT_SIZE="-0.27224430208860556" ORDER="146" O_E="-3.5" SE="0.42320736951515897" STUDY_ID="STD-Halikas-1995" TOTAL_1="50" TOTAL_2="50" VAR="5.583333333333334" WEIGHT="11.150129283627681"/>
<DICH_DATA CI_END="1.120281514998092" CI_START="0.043525280893605814" EFFECT_SIZE="0.22081795130877888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.04932717003409047" LOG_CI_START="-1.3612584174501632" LOG_EFFECT_SIZE="-0.6559656237080363" ORDER="147" O_E="-2.1999999999999993" SE="0.8285849565995211" STUDY_ID="STD-Katz-1990-a" TOTAL_1="18" TOTAL_2="12" VAR="1.456551724137931" WEIGHT="2.9087892595394744"/>
<DICH_DATA CI_END="1.1131976865271505" CI_START="0.21971068152891587" EFFECT_SIZE="0.49455173883355485" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="35" LOG_CI_END="0.04657229510223476" LOG_CI_START="-0.6581488287585942" LOG_EFFECT_SIZE="-0.3057882668281797" ORDER="148" O_E="-4.10891089108911" SE="0.4139566765816747" STUDY_ID="STD-Meignan_x002d_Debray-1990" TOTAL_1="53" TOTAL_2="48" VAR="5.8356631702774235" WEIGHT="11.654041576889167"/>
<DICH_DATA CI_END="1.2824616448679687" CI_START="0.09979136255331635" EFFECT_SIZE="0.3577409607016533" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="32" LOG_CI_END="0.10804438534620729" LOG_CI_START="-1.0009070474678414" LOG_EFFECT_SIZE="-0.4464313310608172" ORDER="149" O_E="-2.422535211267604" SE="0.6514035610330967" STUDY_ID="STD-Nair-1995" TOTAL_1="36" TOTAL_2="35" VAR="2.3566752628446737" WEIGHT="4.706370243626034"/>
<DICH_DATA CI_END="0.7541956048961695" CI_START="0.36015716376749096" EFFECT_SIZE="0.5211803430534497" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="275" LOG_CI_END="-0.122516002790784" LOG_CI_START="-0.4435079423929169" LOG_EFFECT_SIZE="-0.2830119725918505" ORDER="150" O_E="-18.329770992366406" SE="0.18855225425801994" STUDY_ID="STD-Tollefson-1993" TOTAL_1="326" TOTAL_2="329" VAR="28.127850294218437" WEIGHT="56.17238816436904"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.193468181824545" CI_END="0.48088193042427224" CI_START="0.17648139457670572" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2913189209577949" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-0.3179615416295944" LOG_CI_START="-0.753301073044326" LOG_EFFECT_SIZE="-0.5356313073369603" METHOD="PETO" NO="2" P_CHI2="0.8217789694780822" P_Q="1.0" P_Z="1.4142542633276516E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="181" TOTAL_2="131" WEIGHT="99.99999999999997" Z="4.822985259165103">
<NAME>Other categories of depression</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6710135860128262" CI_START="0.06788928378235932" EFFECT_SIZE="0.21343531048690922" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.17326868658112848" LOG_CI_START="-1.168198773016726" LOG_EFFECT_SIZE="-0.6707337297989272" ORDER="151" O_E="-4.521739130434783" SE="0.5844268577556269" STUDY_ID="STD-De-Leo-1984" TOTAL_1="24" TOTAL_2="22" VAR="2.9277882797731567" WEIGHT="19.14569265367444"/>
<DICH_DATA CI_END="1.752531745725184" CI_START="0.09245239142120978" EFFECT_SIZE="0.4025242240336361" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" LOG_CI_END="0.24366589361067942" LOG_CI_START="-1.0340818506745977" LOG_EFFECT_SIZE="-0.39520797853195905" ORDER="152" O_E="-1.615384615384615" SE="0.7505553499465134" STUDY_ID="STD-Gerner-1980-a" TOTAL_1="19" TOTAL_2="20" VAR="1.775147928994083" WEIGHT="11.608228948153542"/>
<DICH_DATA CI_END="1.1074367161053393" CI_START="0.15844764543682094" EFFECT_SIZE="0.4188922774857232" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="35" LOG_CI_END="0.04431891807207822" LOG_CI_START="-0.8001142101271597" LOG_EFFECT_SIZE="-0.3778976460275407" ORDER="153" O_E="-3.5365853658536572" SE="0.49602419951563126" STUDY_ID="STD-Hammond-1993" TOTAL_1="39" TOTAL_2="43" VAR="4.064379668186926" WEIGHT="26.578207342567573"/>
<DICH_DATA CI_END="0.8635962944781304" CI_START="0.0511317252077569" EFFECT_SIZE="0.21013607120076472" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="-0.06368922980602487" LOG_CI_START="-1.2913095537321209" LOG_EFFECT_SIZE="-0.6774993917690729" ORDER="154" O_E="-3.0" SE="0.7211102550927979" STUDY_ID="STD-Jansen-1982" TOTAL_1="20" TOTAL_2="20" VAR="1.923076923076923" WEIGHT="12.575581360499667"/>
<DICH_DATA CI_END="2.509836288379832" CI_START="0.09982601600588706" EFFECT_SIZE="0.5005466586602704" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="5" LOG_CI_END="0.39964539424118284" LOG_CI_START="-1.000756260963278" LOG_EFFECT_SIZE="-0.3005554333610476" ORDER="155" O_E="-1.0227272727272734" SE="0.8226028643670931" STUDY_ID="STD-Kane-1983" TOTAL_1="37" TOTAL_2="7" VAR="1.4778132807995388" WEIGHT="9.663867797127201"/>
<DICH_DATA CI_END="0.580359956247213" CI_START="0.06316990929853392" EFFECT_SIZE="0.19147137069712944" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="-0.23630256070849534" LOG_CI_START="-1.1994897466797099" LOG_EFFECT_SIZE="-0.7178961536941026" ORDER="156" O_E="-5.16393442622951" SE="0.565780920892957" STUDY_ID="STD-Merideth-1984" TOTAL_1="42" TOTAL_2="19" VAR="3.123945176027949" WEIGHT="20.428421897977564"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Low Dose antidepressants</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low dose recovery</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.530997966278771" CI_END="0.4024143542360803" CI_START="-5.4997158743667125" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5486507600653163" ESTIMABLE="YES" I2="60.489893183507306" I2_Q="60.489893183507306" ID="CMP-009.02" NO="2" P_CHI2="0.11162991090614016" P_Q="0.11162991090614016" P_Z="0.0905128576145257" Q="2.530997966278771" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="1.6926985699809542">
<NAME>Observer rating scales</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7501004954512638" CI_START="-8.849899504548736" DF="0.0" EFFECT_SIZE="-4.8" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.01" NO="1" P_CHI2="1.0" P_Z="0.02018033864283174" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="13" WEIGHT="53.0968908346941" Z="2.322977919631252">
<NAME>Doxepin</NAME>
<CONT_DATA CI_END="-0.7501004954512638" CI_START="-8.849899504548736" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="11.5" ORDER="157" SD_1="3.8" SD_2="6.2" SE="2.0663132264132535" STUDY_ID="STD-Lakshmanan-1986" TOTAL_1="11" TOTAL_2="13" WEIGHT="53.0968908346941"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.309014701744552" CI_START="-4.309014701744552" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-009.02.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="23" WEIGHT="46.90310916530591" Z="0.0">
<NAME>Lofepramine</NAME>
<CONT_DATA CI_END="4.309014701744552" CI_START="-4.309014701744552" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="7.4" ORDER="6" SD_1="8.6" SD_2="6.1" SE="2.1985172869162444" STUDY_ID="STD-Tan-1994" TOTAL_1="23" TOTAL_2="23" WEIGHT="46.90310916530591"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>